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ABSTRACT 
 
 
 This study examined the relationship between abstinence self-efficacy (ASE), depression, 
psychological distress and treatment outcomes in 18 to 24 year olds with substance 
dependence. Three hundred and three participants completed questionnaires and 
interviews at three time points during a 28-day twelve-step based inpatient program, and 
at 1-month and 3-months post-discharge. ASE was measured with the Alcohol and Drug 
Use Self-Efficacy scale; psychological distress was assessed with the Brief Symptom 
Inventory 18; and depression diagnoses were determined from the Structured Clinical 
Interview for the DSM-IV. We tested the association between intake ASE, distress, and 
depression. Random coefficient regression analyses focused on changes in ASE during 
and after treatment, with distress and depression included as moderators. We used 
distress and depression to predict post-treatment outcomes using ordinary least squares 
regression. At intake, individuals with depression and high distress had significantly 
lower ASE. During treatment, depression and distress did not moderate changes in ASE, 
although individuals with depression and high distress had consistently lower ASE 
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throughout treatment. Depression and distress did not predict treatment outcomes, in part 
because of invariability in 1- and 3-month outcomes. Post-treatment, ASE did not change 
in a consistent manner, and changes for the most part were not moderated by depression 
or distress. Among the abstinent, changes in post-treatment ASE did depend on distress, 
in that those with above average distress at end of treatment increased in ASE from end 
of treatment to the 3-month follow-up. ASE is a potential byproduct of 12-step based 
treatment, but on the whole does not behave differently for the depressed versus non-
depressed. 
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INTRODUCTION 
“Unless people believe they can produce desired effects by their actions they have little 
incentive to act or to persevere in the face of difficulties.” (Bandura, 2004, pp. 621-622) 
 
 Although the transition to adulthood in the United States can be a time of great 
change and opportunity, it also has a dark side: levels of risky behaviors peak. Eighteen 
to 25-year-olds are more likely than any other age group to use illicit drugs, drive while 
under the influence of drugs, and binge drink (Substance Abuse and Mental Health 
Services Administration [SAMHSA], 2005, 2007). These risk behaviors correspond with 
the period of change and exploration termed emerging adulthood (Arnett, 2000). 
Spanning from 18 to 25 years of age, this period is characterized by a lack of 
demographic stability. Frequent variation in romantic partners, residence, and 
employment is common; few obligations exist. It is a time of lifestyle experimentation 
that often includes alcohol and drug use. This use does not come without consequences - 
emerging adults have the highest rates of past-year alcohol and drug use disorders 
(SAMHSA, 2005, 2007). Yet research focusing on this age group is scarce; 18 to 25 year 
olds are regularly grouped with adults in studies. While this may be appropriate for some 
research, it is not the case for substance misuse. Emerging adults have substance use 
patterns similar to adolescents – they tend to be poly-substance users, engage in sporadic 
but heavy drinking, and experience less withdrawal and physical consequences because 
their using careers are recent (Arnett, 2005; Chung & Maisto, 2006). Like adolescents, 
emerging adults often present for substance abuse treatment at the behest of someone 
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else, which makes it important to consider individual motivation when studying treatment 
outcomes (Chung & Maisto, 2006).  
 When substance use becomes problematic, some adolescents will seek treatment 
to resolve those problems. Treatment outcomes are variable, but most adolescents do 
reduce their substance use post-treatment (Chung & Maisto, 2006). Multiple factors 
predict how individuals will fare post-treatment. One salient predictor is self-efficacy. 
Specific self-efficacy (i.e., abstinence self-efficacy; ASE) to abstain from drinking or 
using drugs is a key predictor of better substance abuse treatment outcomes (McKellar, 
Ilgen, Moos, & Moos, 2008). Depression also predicts outcomes (albeit poorer ones), and 
is of particular interest because 32.75% of adults with alcohol use disorders and 44.26% 
of adults with drug use disorders who present for substance use treatment also meet 
criteria for past-year Major Depression (Grant et al., 2004). The current study aims to 
integrate findings on abstinence self-efficacy and depression by investigating both 
variables in a sample of emerging adults with substance dependence. We begin with an 
introduction to self-efficacy theory, followed by a discussion of comorbid substance 
dependence and depression, and conclude by linking the two.  
Self-Efficacy 
 Social cognitive theory maintains that individuals act as agents in their own lives. 
It presupposes that people can self-regulate and self-reflect, actively shaping their 
environment. Levels of self-efficacy are central to this theory. Self-efficacy expectancies 
are beliefs individuals have about their ability to exercise control over life events 
(Bandura, 1989). Bandura found that, “Perceived self-efficacy was shown to be the 
common pathway through which different modes of influence promote change in 
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different spheres of functioning” (2004, p. 622). Self-efficacy expectancies govern the 
extent to which people feel capable of self-action and change (Bandura, 2004). 
Individuals change when their efficacy and sense of personal mastery increases. 
Theoretically, increases in self-efficacy should be followed by increases in specific 
behavior (Maddux, 1991). 
 Self-efficacy theory holds that individuals will persevere at certain behaviors 
depending on three factors: (1) outcome value (importance), (2) outcome expectancy 
(likelihood of occurring), and (3) self-efficacy expectancy (estimate of personal 
capability; Maddux, 1991). Self-efficacy expectancies are the most relevant to individual 
behavior because they influence commencement of and persistence in adaptive behaviors 
and coping (Maddux, 1991). Outcome expectancies are less important because they 
depend on self-efficacy expectancies and do not add significant utility in studies 
(Maddux, 1991). 
 Self-efficacy expectancies are relevant to multiple aspects of life, including 
health, work achievement, political system improvement, and clinical settings. Bandura 
(2004) cites four ways in which self-efficacy may increase. The first, and most 
influential, involves mastery or performance experiences (e.g., personal successes in 
overcoming obstacles, such as repeatedly turning down a drink at a party). The second 
method is social modeling or vicarious experiences, in which an individual observes 
others overcoming obstacles (e.g., Alcoholics Anonymous [AA], group therapy, inpatient 
role models). The effect of this second method depends on whether a person thinks he or 
she is similar to the person being observed (Maddux, 1991). The third involves social and 
verbal persuasion, when others convince someone that he or she is capable (e.g., 
  4
affirmations from therapist). In this case, the persuader must be trusted by the person or 
seen as an expert. Finally, self-efficacy may vary depending on an individual’s particular 
physical or emotional state (Bandura, 2004). Emotional arousal leads a person to 
associate aversive emotional states with poor performance and failure. Those who feel 
bad are more likely to doubt their capabilities and choose environments in which they are 
more likely to fail (Maddux, 1991). In this way, those who feel depressed have less self-
efficacy, and are less likely to succeed in the tasks they face.  
 Abstinence self-efficacy. For Bandura, self-efficacy is specific: it is most useful 
when applied to particular situations (e.g., social gatherings, emotional states) and 
behaviors (e.g., substance use). High levels of drug and alcohol abstinence self-efficacy 
predict better substance abuse treatment outcomes across genders and treatment settings 
(McKellar et al., 2008; Witkiewitz & Marlatt, 2004). Witkiewitz and Marlatt include 
ASE as a key interpersonal, cognitive determinant of relapse in their relapse prevention 
model. When individuals face high-risk relapse situations, low ASE may inhibit their 
capability to cope with that situation successfully and not drink or use substances 
(Gwaltney, Metrik, Kahler, & Shiffman, 2009). Twelve-step based models do not focus 
explicitly on increased ASE during treatment, but attending AA meetings has been 
associated with higher ASE (Moos, 2008).  
 Independent of treatment modality, ASE generally increases during treatment 
(Goldbeck, Myatt, & Aitchison, 1997; McKellar et al., 2008; Wong et al., 2004). There 
are several reasons why this might occur: individuals may learn specific skills in 
treatment to cope with difficult situations (similar to relapse prevention training); they 
may experience the benefits of sobriety and want to extend those benefits; or they may 
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gain confidence in their ability to remain abstinent because they are able to experience a 
period of sustained abstinence. 
 When measured at varying time points, abstinence self-efficacy consistently 
predicts outcomes. Baseline ASE is as predictive of first smoking lapse as are daily 
reports of ASE (Shiffman et al., 2000). In a sample of adults with alcohol use disorders 
(AUDs), high self-efficacy at baseline predicted remission from AUDs at 3 years (Moos 
& Moos, 2006). A review of 63 alcohol treatment outcomes studies (51 unique) among 
adults at three months post-treatment and beyond found that the strongest predictors of 
treatment outcomes included baseline alcohol-related self-efficacy and psychopathology 
ratings, along with dependence severity, motivation to change, and treatment goal 
(Adamson, Sellman, & Frampton, 2009). Adamson and colleagues found that, among 
those studies that included alcohol-related self-efficacy as a predictor, 100% of the 
studies cited it as a significant predictor. Correspondingly, 83% of the studies found 
motivation to change and 57% found psychopathology to be significant predictors of 
outcomes.  
 ASE ratings at the end of an inpatient detoxification or treatment program 
predicted abstinence status three months post-treatment (Goldbeck et al., 1997). 
Goldbeck and colleagues circumvented the question of motivation by only including 
those who wanted to remain abstinent for at least three months post-treatment. In the 
current study, we included a measure of motivation to assess for covariance between 
motivation and ASE. 
 One hundred percent confidence in ability to remain abstinent at discharge 
(measured by the Situational Confidence Questionnaire; Annis & Graham, 1988) was the 
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strongest predictor of abstinence at one-year post-treatment in an adult male sample 
(Ilgen, McKellar, & Tiet, 2005). Among those in remission at three years, less self-
efficacy at three years predicted relapse by the 16-year follow-up (Moos & Moos, 2006).  
 Abstinence self-efficacy is often measured in relation to specific tempting 
situations. In an outpatient sample of adolescents treated for substance use disorders, 
higher ASE in positive affect situations at treatment intake predicted less drug use during 
treatment (Burleson & Kaminer, 2005). Positive affect situations are those in which an 
individual uses drugs to enhance a positive mood, as compared to negative affect 
situations, where an individual uses to dull negative emotions. 
 When using ASE to predict treatment outcomes, it is important to take into 
account current and prior substance use. Gwaltney and colleagues (2009) reviewed the 
ASE and smoking cessation literature and stated that effect sizes will be overestimated if 
researchers do not control for smoking at the time of assessment. Without making this 
adjustment, ASE may largely reflect smoking behavior. Studies where current smoking 
was not a covariate yielded the highest effect sizes. While still robust, taking current 
smoking behavior into account yielded small to medium effect sizes when predicting 
smoking behavior from prior ASE (Gwaltney et al., 2009). The authors also 
recommended using post-treatment ratings of ASE to predict later use because they may 
be more realistic than overly confident in-treatment ratings. Additionally, because 
estimates of ASE may fluctuate, using them to predict proximal behavior is preferable to 
predicting distal behavior. Despite these cautions, ASE has been found to be one of the 
best predictors of long-term treatment outcomes (Adamson et al., 2009). For example, 
even after controlling for baseline drinking, Greenfield and colleagues (2000) found that 
  7
intake self-efficacy scores on the Situational Confidence Questionnaire (which measures 
confidence to cope with difficult drinking-related situations) predicted number of days 
until first drink among a group of men and women in inpatient alcohol use disorders 
treatment. 
 Most ASE studies have focused on alcohol or tobacco, but one study examined 
cocaine use. When controlling for pre-treatment cocaine use, baseline ASE predicted 
cocaine use outcomes at three-months, but not six-months, in a sample of adult 
residential treatment participants with cocaine dependence (Dolan, Martin, & Rohsenow, 
2008). Interestingly, lower baseline ASE was associated with more depressive symptoms 
as measured by the Beck Depression Inventory (BDI). Depressed individuals may be at a 
disadvantage when trying to recover from substance use because they tend to have lower 
ASE, and lower ASE is associated with poorer outcomes. The relationship between 
depression, ASE, and outcomes has received little attention in the literature. In addition, 
no studies have specifically examined ASE and treatment outcomes in emerging adults. 
The current study aims to address both of these arenas. 
Comorbidity and Substance Use Trajectory 
 Most emerging adults abandon or decrease heavy drinking and drug use as they 
enter their late twenties, but those with high levels of anxiety, hostility, and depression 
continue to drink heavily into adulthood (Costanzo et al., 2007). Because of their unique 
demographic characteristics and high risk for continued substance abuse, research with 
18 to 24 year olds with substance dependence and high levels of psychological distress 
merits particular attention. The combination of Major Depressive Disorder (MDD) and 
substance use disorders puts emerging adults at risk for suicide attempts. For example, in 
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a sample of 1,709 adolescents, 19% of adolescents with MDD attempted suicide, 
compared to 35% of those with MDD and substance use disorders (Rohde, 2009). Major 
Depressive Disorder often prevents emerging adults from completing age-related 
developmental tasks, such as work, social development, and educational attainment 
(Zarate, 2009).  
 Comorbidity between depression and substance use disorders is common. In the 
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 14.50% 
(SE = 0.68) of adults with a diagnosis of substance use disorder in the past year also met 
criteria for Major Depression in the past year (Grant et al., 2004). Among those with a 
diagnosis of Major Depression in the past year, 19.20% (SE = 0.85) also had a comorbid 
substance use disorder in the previous 12 months. The National Comorbidity Replication 
Study found that, among community-dwelling adults with a lifetime diagnosis of MDD, 
24% also met DSM-IV criteria for substance use disorders at some point (Kessler et al., 
2003).  
 For adolescents, the relationship between depression and substance use disorders 
may be stronger than among adults (Rohde, 2009). Comorbid diagnoses are particularly 
prevalent among those who seek treatment for substance use disorders, and among 
depressed treatment-seeking adolescents (Rohde, 2009). Among adults who had past-year 
substance use disorders, 5.81% of those with AUDs sought treatment, and 32.75% (SE = 
4.01) of this smaller group had Major Depression in the past year. Among those with 
drug use disorders (of which 13.10% sought treatment), 44.26% also had comorbid Major 
Depression (Grant et al., 2004). 
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 In teenaged samples, those with both an alcohol use disorder and a diagnosis of 
MDD at outpatient treatment intake relapsed more quickly than those without an MDD 
diagnosis (Cornelius et al., 2004). Moreover, any Axis I disorder combined with a 
substance use disorder has been associated with more substance use post-treatment in 
adolescents (Tomlinson, Brown, & Abrantes, 2004). 
 Although comorbidity increases the likelihood of relapse to substance use and the 
severity of that relapse for both adults and adolescents, this predictive relationship is 
weakened when a lifetime diagnosis of MDD is used as a predictor of relapse instead of a 
current MDD diagnosis or a general measure of depressive symptoms (Bradizza, 
Stasiewicz, & Paas, 2006; Ramo & Brown, 2008). This weaker association may occur 
because past depressive symptoms are less relevant to the current substance use disorder. 
Here, we focus only on studies that used a current measure of depression as a predictor of 
treatment outcomes.  
 In an adult sample with alcohol dependence, a diagnosis of current MDD 
(substance-induced or primary) on admission to hospital-based detoxification was 
significantly related to an earlier time to first drink and relapse following treatment 
(Greenfield et al., 1998). Dodge, Sindelar, & Sinha (2005) found that higher BDI scores 
among adults at outpatient treatment intake predicted less abstinence during the year 
following treatment. With each additional point scored on the BDI, the likelihood of 
abstinence at discharge decreased by 3.5% (Dodge et al., 2005). Age also predicted 
abstinence in this study. The younger the individual, the more likely he or she was to 
relapse. This adds import to the study of mechanisms of recovery in a younger 
population.  
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 In a college sample, Geisner, Larimer, and Neighbors (2004) looked at the 
prevalence of psychological distress and alcohol use via the Brief Symptom Inventory. 
With low psychological distress, both men and women consumed a similar amount of 
alcohol. Those participants who reported more psychological distress consumed 
significantly more alcohol. The relation between psychological distress and alcohol 
consumption was significantly stronger among men. When psychological distress was 
high, men drank significantly more alcohol than women and experienced significantly 
more problems related to their alcohol use. 
 Using psychological distress as a continuous variable, Flynn and colleagues 
(2004) found that high Brief Symptom Inventory scores from the first month of adult 
outpatient or inpatient treatment for substance use predicted poorer two-year outcomes. 
When psychological distress at two years was taken into account, this relationship 
became non-significant for illicit drug use but not alcohol use. Among those who did not 
drink post-treatment, psychological distress as measured by the Brief Symptom Inventory 
decreased; it did not change for those who resumed drinking (Flynn et al., 2004). In 
general, high levels of psychological distress may be a marker of greater probability of 
return to substance use.  
Situational Predictors of Relapse 
 Beyond influencing treatment outcomes, comorbidity and psychological distress 
also influence which situations pose the greatest risk for relapse. The relapse prevention 
model (Witkiewitz & Marlatt, 2004) emphasizes the importance of negative emotional 
states to relapse. Following treatment for substance use disorders, situational relapse 
precipitants differ according to age. Studies comparing relapse precursors have focused 
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primarily on adolescents and adults (e.g., Ramo & Brown, 2008); information on 
emerging adults is absent. In general, adolescents (12 to 18 year olds) report a first 
relapse in social situations, while adults cite negative emotions or negative interpersonal 
conflict as key relapse precipitants (Chung & Maisto, 2006). Comparing adults and teens 
that relapsed in the 18 months following treatment, Ramo and Brown found similar but 
more complex precipitant patterns in social situations. Most adults reported relapsing in 
response to social situations in which they felt tempted to drink. For teenagers, the initial 
relapse came in social situations when trying to enhance a positive emotional state. 
Overall, teenagers were five times more likely than adults to relapse in response to a 
positive emotional state (Ramo & Brown, 2008).  
 Ramo and Brown's findings (2008) are limited because the adult and adolescent 
sample differed in key characteristics – the adult sample was primarily male and over half 
of the teen sample met DSM-III-R criteria for a depressive disorder. Results from a teen 
sample with high rates of comorbid diagnoses cannot be generalized to those without 
because emotional state may play a role in primary relapse precipitants (Ramo & Brown, 
2008). While differences in relapse precipitants have been noted in adolescents and 
adults, the particular relapse precipitants for emerging adults are unclear, as are the 
differences between those with and without psychological disorders or distress.  
Self-Efficacy and Depression 
 Self-efficacy theory offers perspective on the role of cognition in depression, 
particularly expectancies for control (Maddux, 1991). Within this framework, depression 
occurs when individuals want something to happen, believe it is a common event, but 
have low self-efficacy expectancies (Maddux, 1991). Low self-efficacy expectancies 
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influence depression in that individuals feel like they cannot: (1) perform effectively, (2) 
develop good relationships, or (3) control ruminations (Maddux & Meier, 1995). 
Cognitive behavioral therapy targets these low self-efficacy expectancies by addressing 
irrational thoughts and automatic negative thoughts (e.g., I’ll never be sober). With low 
self-efficacy expectancies and low outcome expectancies, life events seem 
uncontrollable. This feeling of powerlessness leads to not emitting behavior, acting 
passively, and ending up in a sub-optimal environment. For example, individuals with 
depression and substance dependence may not choose new friends who are supportive of 
sobriety because of their depression, may not feel good about themselves, and are likely 
to have a hard time engaging in treatment and AA. In general, depression is associated 
with lower overall self-efficacy (Dolan et al., 2008). Depression is a product of, and 
manifest in, numerous situations and behaviors where low self-efficacy expectancies are 
present. In a study using Ecological Momentary Assessment to monitor levels of 
abstinence self-efficacy and negative affect during an attempt to quit smoking, negative 
affect was associated with a decrease in ASE (Gwaltney, Shiffman, & Sayette, 2005). 
  While ASE is lower among those with comorbid diagnoses, it still retains its 
predictive power for treatment outcomes. In a sample with co-occurring disorders (2/3 
mood disorders), greater baseline ASE predicted less cocaine and alcohol use six months 
post-treatment entry (Warren, Stein, & Grella, 2007). Decreases in the severity of 
substance use disorders and MDD during the year following treatment predicted greater 
self-efficacy at one-year post-treatment (McKellar et al., 2008). Specific situations where 
individuals report low ASE (i.e., high risk situations) tend to be situations where they will 
relapse (Gwaltney et al., 2005). Adolescents who have low ASE and psychiatric 
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symptoms seem to be most vulnerable to relapse in negative situations following 
instances of conflict, life stress and negative emotional states (Ramo, Anderson, Tate, & 
Brown, 2005). 
 Understanding the relationship between ASE and depression can help to 
individualize treatment and improve treatment outcomes. Individuals with comorbid 
substance use disorders and other Axis I disorders are doubly disadvantaged: comorbidity 
predicts worse outcomes and is associated with lower self-efficacy, and lower ASE also 
predicts worse treatment outcomes (Burleson & Kaminer, 2005; Moss, Kirisci, & 
Mezzich, 1994).  
Hypotheses 
 The current study examined levels of drug and alcohol abstinence self-efficacy 
among 18- to 24-year-olds during and after a month of inpatient treatment for substance 
use disorders.  Specific comparisons focused on levels of psychological distress (as 
measured by the Brief Symptom Inventory 18) and depression status. This focus is 
relevant because psychological distress and depression are related to lower ASE (Dolan 
et al., 2008). Understanding how ASE shifts during and after treatment may inform 
specific interventions for those with comorbid disorders. Such an investigation is 
particularly relevant among 18- to 24-year-olds because they have high rates of comorbid 
Major Depressive Disorder and substance use disorders, but few investigations have 
concentrated on them.  
 Specific study hypotheses included: (1) Baseline depression status and 
psychological distress both would be associated with lower overall ASE at baseline and 
lower ASE in negative affect situations at baseline. (2) Depression and psychological 
  14
distress would moderate changes in ASE during treatment: increases would be greater for 
those without depression or high baseline psychological distress. (3) Depression and 
distress would predict treatment outcomes, and levels of psychological distress at the end 
of treatment would better predict substance use at follow-ups than a diagnosis of 
depression at baseline. (4) For those who remained abstinent from the end of treatment to 
the 3-month follow-up, ASE would increase more than in those who relapsed. Among 
those who were abstinent, this increase would depend on the absence of depression or 
psychological distress, i.e. ASE would remain static for those with depression or high 
psychological distress, while increasing for those without depression or with lower levels 
of psychological distress. 
Method 
Participants 
 This was a secondary investigation using data from a larger study on young adult 
treatment outcomes and 12-Step group involvement. Study participants were recruited 
from the Hazelden Center for Youth and Families (CYF) between October 2006 and 
April 2008. For the larger study, inclusion criteria included: admittance to the CYF 
inpatient program, and being 18 years of age or older at the time of admittance. Exclusion 
criteria included overt cognitive difficulties or psychosis (if notable during the 
recruitment process by research assistants). No one was excluded from the study for these 
reasons because treatment at CYF requires a certain minimal level of functioning.   
 CYF is located in Plymouth, MN and is part of the Hazelden Foundation, a non-
profit organization with substance dependence treatment facilities nationwide. CYF is 
described as a co-occurring disorders treatment facility with an emphasis on substance 
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dependence. Treatment is grounded in the 12-step based Minnesota model of treatment 
and supplemented with other models (e.g., cognitive behavioral therapy, motivational 
interviewing). Separated by gender, key components of the 28-day inpatient program 
include individual and group therapy, mental health assessment, individual assignments 
related to treatment goals and the 12 steps of AA, education through bibliotherapy and 
daily lectures, and recreational and spiritual care. Patients at CYF range in age from 14 to 
25 years, with a mean age of 18 years.  
 Research assistants approached 367 individuals for study participation. Of these, 
47 (12.8%) declined to participate, citing a lack of interest (n = 15), a desire to avoid 
follow-ups (n = 8), the study taking too much time (n = 8), preferring to focus on 
treatment (n = 6), not expecting to finish treatment (n = 5), and other miscellaneous 
reasons (n = 5; e.g., uncomfortable withdrawal symptoms, legal advice). A chi-squared 
test and an independent t-test were executed to test for significant differences in gender 
and age between those who consented versus those who declined to participate in the 
study. While there was no difference in gender between the two groups, there was a 
statistically significant difference in age, t(360) = p <.05; those who declined to 
participate were younger. The actual age difference between the two groups was slight, 
with a mean of 19.8 (SD = 1.4) among non-participants and a mean of 20.4 (SD = 1.6) 
among participants.  
 Out of the 320 individuals who agreed to participate in the study, 303 (95%) 
completed the baseline interview and are included in analyses. In an independent samples 
t-test, no significant differences in age, gender, or length of stay were found between 
those who completed the baseline interview and those who did not.  
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 The sample of 303 participants included 79 females (26%) and 224 males (74%). 
This gender split reflects the male to female ratio at CYF. Participants were, on average, 
20.4 years old (SD = 1.6), and spent 25 days at CYF (SD = 6.47). Ninety-five percent of 
the sample was Caucasian. Fifty participants had not completed high school (16.5%), 132 
(43.6%) had a H.S. Diploma or GED, 115 had completed some college (38.0%), and five 
had a college or vocational degree (1.6%). On the Structured Clinical Interview for the 
DSM-IV (SCID-I/P; First, Spitzer, Gibbon, & Williams, 1995), 65.7% of participants met 
DSM-IV criteria for an Axis I diagnosis in addition to the substance use disorders 
diagnoses (excluding psychotic, somatoform and adjustment disorders). At baseline, most 
participants reported alcohol (n = 81; 26.7%) or marijuana (n = 81; 26.7%) as their 
substances of choice. Opiates (n = 67; 22.1%), cocaine (n = 36; 11.8%), and 
methamphetamines (n = 15; 5%) also were cited frequently as substances of choice.  
 In the 90 days prior to treatment intake, participants reported using substances an 
average of 68.51 days (SD = 25.25) and had a mean score of 64.99 (SD = 24.77) on the 
Inventory of Drug Use Consequences (InDUC-2R; Tonigan & Miller, 2002). Reported 
InDUC-2R scores ranged from 0 to 135, out of a possible total of 135. At intake, mean 
Alcohol and Drug Use Self-Efficacy scale (ADUSE; Brown, Seraganian, Tremblay, & 
Annis, 2002) total score was 2.0 (SD = 2.9) and mean Brief Symptom Inventory 18 
Global Severity Index score (BSI 18; Derogatis, 2000) was 63.3 (SD = 10.1). 
 Because of its pertinence to the study hypotheses, Table 1 displays demographic 
information separated by depression status at intake. Participants were considered 
“depressed” if they met DSM-IV criteria on the SCID-I/P for past-month Substance-
Induced Mood Disorder with depressive features (n = 51) or past-month Major 
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Depressive Disorder (n = 48). Chi-square tests were conducted to test for differences in 
ethnicity, gender, drug of choice, and education between depressed and non-depressed 
participants. There were no significant differences in ethnicity or education. The gender 
test was significant, χ2 (1, N = 303) = 5.219, p < .05, such that females made up a larger 
proportion of the depressed group than expected, and a larger proportion than in the non-
depressed group. The results for drug of choice were also significant, χ2 (7, N = 303) = 
17.217, p < .05. Differences in expected drug of choice were found for opiates and 
marijuana: a higher proportion of the depressed group reported opiates as their drug of 
choice, while a higher proportion of the non-depressed group reported marijuana as their 
drug of choice. Independent samples t-tests were conducted to test for differences 
between depressed and non-depressed individuals in age, length of stay, pre-treatment 
use, and scores on the BSI 18, ADUSE, and InDUC-2R. Significant differences were 
found in pre-treatment use and on the BSI 18, ADUSE, and InDUC-2R (see Table 1).  
Procedure 
 One of two research assistants (B.G. being one) approached potential participants 
for recruitment during their first three days of inpatient treatment. To achieve a balanced 
age sample, every other 18 to 20 year old was approached for study participation, while 
each individual 21 years and older was approached for study participation. Study 
participants gave informed consent and were scheduled for a baseline interview within 
their first seven days of treatment. An independent review board, Schulmann Associates 
IRB, approved the larger study.  
 Participants were given a packet of self-report forms to complete prior to the 
baseline interview. The baseline interview included the SCID-I/P (First, Spitzer, Gibbon, 
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& Williams, 2002) and was the longest session, ranging from 90 to 180 minutes (see 
Appendix for other study-relevant measures administered at baseline). The SCID-I/P was 
given in full, minus the psychotic, adjustment, and somatoform disorders modules. The 
bachelor’s level research assistants who administered the SCID-I/P received extensive 
training in the instrument prior to conducting research interviews. Each SCID-I/P was 
audio-recorded; a research scientist listened to all tapes in the first month of recruitment 
and two tapes from each week thereafter to verify diagnostic agreement between herself 
and the research assistant. No reliability statistics were computed for the SCID-I/P. 
 Participants completed a mid-treatment research assessment session 
approximately 14 days into treatment and an end of treatment session prior to treatment 
discharge. The mid- and end of treatment sessions included self-report and interview 
components (see Appendix).  
 To assist in follow-up tracking, detailed information about the participants and 
their contacts was obtained at the baseline interview and verified in the end of treatment 
session prior to treatment departure. Research assistants obtained release of information 
forms for significant individuals in the participant’s life, as well as for aftercare facilities 
such as halfway houses and continuing care facilities. These forms were for tracking 
purposes only, and they allowed research assistants to disclose that they were calling 
from Hazelden about a research study and inquire regarding the participant’s 
whereabouts. 
 Follow-ups occurred at one-, three-, six-, and 12-months following treatment 
discharge. Only the one- and three-month follow-ups were analyzed in the current study. 
Each follow-up session included an interview and self-report component. The interview 
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component was completed by phone, or in-person at CYF or Fellowship Club, a 
Hazelden-owned halfway house. Interviews were conducted in person only if the 
participant lived within a 200-mile radius of Plymouth, MN, and was willing to come in 
for the session. If an interview was conducted in person and the individual reported no 
drug or alcohol use in the follow-up period, an Intercept Oral Fluid Drug Test was given 
to verify the “no-use” report. Those who reported alcohol or drug use in the period of 
interest did not receive the Intercept Oral Fluid Drug Test. Self-report measures were 
completed online or in a pen and paper version. Some participants preferred to complete 
the self-report measures verbally by phone; this was an acceptable option. 
 Following each completed research session (defined as completing both interview 
and self-report portions) study participants were mailed a check as compensation. The 
per-session compensation was scaled according to session duration (e.g., $30 for 90 
minute baseline vs. $10 for 20 minute mid-treatment session) and length of time since 
treatment departure (e.g., $20 for 1-month follow-up, $50 for 12-month follow-up). If all 
research sessions were completed, participants received a total of $210. At the 1-month 
follow-up, 84.8% of participants (n = 251) completed the interview (e.g., Brief Symptom 
Inventory 18, Form 90, & Commitment to Sobriety Scale), 42.9%  (n = 127) completed 
the self-report forms (e.g., Alcohol and Drug Use Self-Efficacy scale), and seven 
participants withdrew from the study. At 3-months, 84.8% (n = 245) completed the 
interview, 64.0% (n = 185) completed the self-report forms, and an additional seven 
participants withdrew. Reasons for study withdrawal were not recorded. 
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Measures 
 The Appendix details the frequency and timing of measure administration. The 
listed six and 12-month assessments were not included in the present analyses. Additional 
measures were given at all time points, but they were not listed because they are not 
pertinent to the current investigation.  
 Demographics. CYF treatment attendees provide information about their gender, 
age, ethnicity, and education as part of the routine treatment intake process. This 
information was taken from their treatment records for the purposes of this study. 
 Psychological distress. The Brief Symptom Inventory 18 (BSI 18; Derogatis, 
2000) is a shortened version of the Brief Symptom Inventory (Derogatis, 1993), which in 
turn is based on the Symptom Checklist-90-R (Derogatis, 1994). In the current study, the 
BSI 18 was administered at each time point and provided a continuous measure of 
psychological distress. Eighteen questions reference the previous week and are rated on a 
zero (not at all) to four (extremely) Likert scale. The total score is the Global Severity 
Index (GSI); three sets of six questions are used to create Anxiety, Depression, and 
Somatization subscales. Male and female scores are normed separately and a T-score 
greater than 63 is considered the cut-off for psychological distress (Derogatis, 2000).  
 The BSI 18 has been normed in community and oncology samples and has 
acceptable test-retest reliability and internal consistency (Derogatis, 2000). In a sample of 
cancer patients, Zabora and colleagues (2001) found that the full BSI 18 had a 
Cronbach’s alpha of .89, but a factor analysis revealed four subscales instead of the 
hypothesized three. The fourth factor combined panic and suicidal thoughts. A second 
study in a sample of Central American refugees and immigrants found that the items on 
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the BSI 18 were internally consistent (subscales: α = 0.81, GSI: α = 0.91; Asner-Self, 
Schreiber, & Marotta, 2006). Despite this internal consistency, the authors determined 
that the three dimensions of the BSI 18 are not robust – the factor analysis yielded only 
one factor. In light of these studies, the measure is best conceptualized as a good index of 
global psychological distress, but not a diagnostic tool. In addition, because it 
theoretically combines anxiety, somatization, and depression items, it is not synonymous 
with SCID-I/P depression diagnoses.  
 Depression status. The SCID-I/P is a semi-structured interview for the primary 
DSM-IV Axis I diagnoses (First et al., 2002). Diagnoses of past-month MDD and past-
month Substance-Induced Mood Disorder with depressive features were combined for a 
dichotomous predictor variable of depression present/absent. Prior to combining the 
SCID-I/P depression categories, we tested for differences between the two depression 
groups using an independent samples t-test and a chi-square test. Persons in the two 
depression diagnosis groups did not differ in length of stay at CYF, age, gender, InDUC-
2R or BSI 18 scores, but did differ in their Form 90 pre-treatment use scores, t(97) = -
2.87, p = .005 (see Table 2). Despite this difference, the two categories were combined 
because we are primarily concerned with the two groups having equal levels of distress at 
intake, which was demonstrated by similar scores on the BSI 18. 
 Reliability for structured interviews can be assessed through joint or test-retest 
reliability. Joint reliability is inherently higher because a second rater listens to the first 
rater’s interview, which provides some indication of what the first interviewer selected 
because of skip codes. Test-retest reliability involves independent interviews with the 
same client. For MDD, Kappas for joint reliability were excellent (0.80 to 0.93), while 
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Kappas for test-retest reliability were fair, ranging from 0.61 to 0.64 (First, Spitzer, 
Gibbon, & Williams, 1995; Segal, Kabacoff, Hersen, Van Hasselt, & Ryan, 1995; Skre, 
Onstad, Torgersen, & Kringlen, 1991; Zanarini & Frankenburg, 2001; Zanarini et al., 
2000). Reliability in diagnosing Substance-Induced Mood Disorder with the SCID has 
not been reported in the literature. 
 Several studies have found lower reliability when using the SCID for comorbid 
diagnoses among those with substance use disorders. In an inpatient population with 
substance use disorders, Kranzler and colleagues (1996) found very good validity of the 
SCID in diagnosing substance use disorders, but only moderate to poor validity for 
diagnosing other disorders. The authors did find that SCID MDD diagnoses had 
concurrent validity, in that intake Addiction Severity Index scores distinguished between 
those with or without diagnoses of MDD. Ross and colleagues (1995) found that, while 
the SCID had good test-retest reliability for substance use disorders, the test-retest 
reliability of the SCID over one week was 0.32 for lifetime MDD, which is considered 
poor. However, only 16 of the 80 potential participants with substance use disorders in 
this sample had MDD.  
 Low reliability in diagnosing MDD among those with substance use disorders 
may result from a discrepancy in determining whether MDD is primary or secondary; 
substance use often mimics symptoms of other mental disorders (Grant et al., 2004). 
Because of this, the Brief Symptom Inventory 18 (BSI 18) offered an alternative measure 
of psychopathology in the current study.  
 Substance use frequency and general functioning. A modified version of the 
Form-90 (Project MATCH Research Group, 1993) was used to assess general functioning 
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and frequency of substance use. Study-relevant variables included percent days abstinent 
(PDA) from any substance (other than nicotine) at follow-ups, days using in the 90 days 
before intake, pre-treatment lifetime AA attendance, and participation in additional 
treatment for substance dependence issues in the post-treatment periods. 
 The Form-90 instruments were developed for Project MATCH to assess alcohol 
consumption using a combination of a consumption grid and timeline follow-back (Miller 
& Del Boca, 1994). This family of instruments has shown good test-retest reliability and 
validity across samples, including adolescents (Rice, 2007; Slesnick & Tonigan, 2004; 
Tonigan, Miller, & Brown, 1997). In a sub-group of participants in Project MATCH, 
Form 90 test-retest reliability for the same interviewer was excellent for recent alcohol 
and drug use and days in psychological treatment (ICCs = 0.89 - .99). For recent AA 
attendance, test-retest reliability was fair (ICC = 0.59). Among different interviewers at 
the same site, test-retest reliability was variable, ranging from 0.24 for tranquilizers to 1.0 
for marijuana, hallucinogens, and sedatives (Tonigan et al., 1997). Alternate versions of 
the form have been developed (e.g. Form-90d for drug use). Form-90d demonstrated 
excellent reliability in measuring illicit drug use, residential living, and 12-step 
attendance in an adult outpatient sample (ICCs = 0.75 - 0.82; Westerberg, Tonigan, & 
Miller, 1998). 
Substance use consequences. The InDUC-2R (Tonigan & Miller, 2002) was 
administered in self-report form to gauge consequences from alcohol and other drug use 
in the 90 days prior to treatment (baseline version) and in the period since last contact 
(follow-up versions). The InDUC-2R has 50 questions scored on a Likert scale from zero 
to three (0 = never, 1 = once or a few times, 2 = once or twice a week, 3 = daily or almost 
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daily). Subscales of the InDUC-2R include physical, interpersonal, and intrapersonal 
consequences, impulse control, and social responsibility. Five of the 50 questions 
constitute a ‘control’ scale meant to catch careless or dishonest responding.  
 Tonigan and Miller (2002) evaluated the InDUC-2R in a clinical outpatient 
sample. Administered pre- and post-treatment, the InDUC-2R was sensitive to 
consequences after treatment and provided different information than post-treatment 
substance use measures. Blanchard, Morgenstern, Morgan, Labouvie, & Bux (2003) 
examined the psychometric properties of the InDUC-2R and found high internal 
consistency for the entire scale (α = 0.96). The scale loaded strongly on one factor, 
suggesting that the InDUC-2R is best conceptualized as a single measure of 
consequences. Gillaspy and Campbell (2006) further investigated the psychometric 
properties of the InDUC-2R in an adult male sample at an inpatient VA substance use 
disorders treatment center. Participants completed the InDUC-2R at treatment entry and 
one month following treatment discharge. The authors found excellent internal 
consistency for the scale (α = 0.96 at intake, α = 0.98 at follow-up) and low convergent 
validity with numbers of drink per drinking day (r = 0.17). This suggests that the InDUC-
2R measures a different aspect of treatment outcomes than alcohol and drug 
consumption. InDUC-2R scores changed between measurement points (d = 1.39), 
suggesting that the measure can sensitively detect changes due to treatment. Like 
Blanchard and colleagues, Gillaspy and Campbell found significant redundancy between 
subscales, pointing to a preference for the total score.   
 Based on these findings, the InDUC-2R was used in addition to the Form-90 to 
capture a different aspect of treatment outcomes. The overall score was used as a measure 
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of consequences, excluding the five “control” questions meant to detect careless 
responding.  
Abstinence self-efficacy. The Alcohol and Drug Use Self-Efficacy (ADUSE) 
scale (Brown et al., 2002) is a modified version of the Alcohol Abstinence Self-Efficacy 
scale (AASE; DiClemente, Carbonari, Montgomery, & Hughes, 1994) that inquires about 
drug and alcohol use. Participants completed this measure at each assessment point. 
Twenty duplicate questions ask first about temptation to drink or use in different 
situations and then about confidence to avoid using in those same situations, for a total of 
40 questions rated on a Likert scale from 0 (not at all) to 4 (extremely) in our study. The 
usual scaling of this measure is from 1 to 5. The “confidence” questions form an index of 
abstinence self-efficacy. DiClemente and colleagues constructed the AASE from Marlatt 
and Gordon’s relapse categories (1985). Subscales include Negative Affect, 
Social/Positive, Physical and Other Concerns, and Craving/Urges situations. 
The psychometric properties of the ADUSE have not been evaluated; it has been 
used in only one published study (Brown et al., 2002). The closely related AASE 
demonstrated excellent reliability in a treatment-seeking outpatient sample with alcohol 
dependence (α = 0.81-0.88 for subscales, α = 0.92 for the total scale; DiClemente et al., 
1994). DiClemente and colleagues found that the AASE was unrelated to motivation (as 
measured by the University of Rhode Island Change Assessment Scale), which provides 
evidence for the scale’s discriminant validity. 
Hiller, Broome, Knight, and Simpson (2000) adapted the AASE for drug use in a 
residential treatment sample on probation. Unlike Brown and colleagues (2002), they did 
not mention receiving permission from DiClemente to adapt the scale, did not use the 
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name ADUSE, and inquired only about drug use, instead of the combination of alcohol 
and drugs found on the ADUSE. Hiller and colleagues found the same four subscales as 
DiClemente et al. in a confirmatory factor analysis, as well as high construct validity for 
their measure of ASE. 
We computed an internal consistency estimate of the ADUSE. The scale 
demonstrated excellent reliability at intake, with an overall alpha of 0.94 (20 items, N = 
295). Subscales also demonstrated good reliability (∝ = 0.86 – 0.91). These values are 
similar to reliability estimates for the AASE (DiClemente et al., 1994). For the ADUSE, 
we used item means for missing values because individual items ranged widely in their 
correlation with the total ADUSE score.  
 Motivation. The Commitment to Sobriety Scale (CSS) was administered verbally 
at all time points except mid-treatment. John F. Kelly, PhD, a principal investigator on 
the larger study, developed the measure (J. F. Kelly, personal communication, June 3, 
2009). It includes nine questions assessing desire for sobriety, rated on a Likert scale 
from one (strongly disagree) to six (strongly agree; α = 0.68 at intake). We combined 
questions 2 (“I am totally committed to staying off of alcohol/drugs”) and 3 (“I will do 
whatever it takes to recover from my addiction”) to create a ‘motivation’ covariate. 
 Other items on the CSS provided discriminant and convergent validity for the 
construct of abstinence self-efficacy as measured by the ADUSE. The CSS has one 
question regarding importance of sobriety, which was uncorrelated with intake ADUSE 
total score, and one question regarding confidence to stay sober, which was significantly 
and positively related to ADUSE total, r(280) = .342, p < .001. 
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Power Analysis 
 Separate power analyses were conducted for each hypothesis using G*Power 3, 
allowing for a two-tailed alpha and a power of at least .80 (Faul, Erdfelder, Lang, & 
Buchner, 2007). For all hypotheses, our sample of 303 participants was more than 
adequate to detect an effect size of 0.15. 
Statistical Analyses  
 Hypothesis 1. In this exploratory hypothesis, we examined the relationship 
between intake depression status, psychological distress, and abstinence self-efficacy. 
Prior to calculating a multiple correlation coefficient between these variables, we 
examined the intake distribution of the BSI 18, ADUSE, and Form-90 and checked for 
outliers. The relationship between depression status and psychological distress was 
determined in order to assess for multi-collinearity, and we tested for the potential 
covariates of pre-treatment use, baseline motivation, and lifetime AA attendance by 
looking at the relationship between these variables and baseline ADUSE scores. Finally, 
correlations were calculated between depression status from the SCID-I/P, ADUSE 
scales (Total, Negative Affect, Social/Positive, Physical and Other Concerns, and 
Craving and Urges), and BSI 18 scores (Global Severity Index, Anxiety, Depression, 
Somatization). These correlations were repeated while controlling for significant 
covariates. 
 Hypothesis 2. We examined whether mood disorders and psychological distress 
moderated changes in total abstinence self-efficacy (ASE) during treatment. Using the 
three in-treatment assessment points, random coefficient regression was used (RCR; 
Cohen, Cohen, West, & Aiken, 2003) to model within-subject linear changes in total 
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ASE over the course of treatment, and to assess for variability in those linear changes. By 
treating time as both a fixed and a random effect, RCR gives results regarding average 
change as well as the degree to which there is variability between participants in within-
subject slopes for changes in a particular variable. Depression status at baseline (past-
month Substance-Induced Mood Disorder with depressive features or past-month Major 
Depressive Disorder from the SCID-I/P; coded as 0 = no depression, 1 = depression), and 
its interaction with time were then added to the model to determine whether there was a 
main effect of depression on ASE, and whether depression moderated changes in ASE 
over time.  A second series of models was estimated, this time with psychological distress 
(BSI 18 Global Severity Index) as a moderator. One model treated BSI 18 at baseline as a 
fixed effect and then a second model treated BSI as a time-varying covariate. Because 
motivation for treatment, pre-treatment substance use, and pre-treatment Alcoholics 
Anonymous attendance are often related to outcomes, we tested whether these variables 
were significantly related to end of treatment ASE scores. After running the above 
analyses, those variables that were significantly related to ASE were included as 
covariates in the analyses. 
 SAS Proc Mixed was used for these analyses. SAS Proc Mixed is preferred 
because it utilizes modern maximum-likelihood (ML) based approaches for missing data, 
allowing all possible data points to be utilized in the analyses. Proc Mixed utilizes an 
expectation-maximization algorithm for ML estimation of missing values, and a 
participant can be included in the analyses so long as they have two valid data points, 
even if all others are missing. The ML approach is considered state of the art for dealing 
with data that are missing at random (Schafer & Graham, 2002). 
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 Hypothesis 3. In this hypothesis, we examined the effect of depression on 
treatment outcomes. First, we determined how well baseline depression status from the 
SCID-I/P predicted one- and three-month substance use outcomes using ordinary least 
squares regression for the continuous outcomes of InDUC-2R consequences and Form-90 
percent days abstinent. Second, we determined how well end of treatment psychological 
distress (BSI 18 GSI) predicted one- and three-month substance use outcomes, again 
using ordinary least squares regression. Third, we looked at how well psychological 
distress at one-month post-treatment predicted three-month substance use outcomes. 
These separate analyses were meant to elucidate the role of proximal distress (e.g., 1-
month BSI 18 scores) on treatment outcomes, as compared to more distal, ongoing 
distress (e.g., intake depression status).  
 We concluded by determining which measure of depression/distress best 
predicted one-month and three-month outcomes. We included depression status at 
baseline and BSI 18 GSI scores at end of treatment as predictors of one-month substance 
use outcomes, and depression status at baseline and BSI 18 GSI scores at end of 
treatment and one-month to predict three-month substance use outcomes. This analysis 
determined which variable accounted for more variance in outcomes.  
 Because the measures of depression and psychological distress were somewhat 
multicollinear, the final analysis should be interpreted with caution.  The bivariate 
correlation between intake depression status and end of treatment BSI 18 GSI was 
significant, r(261) = .158, p = .01, as was the correlation coefficient between depression 
and 1-month BSI 18 GSI scores, r(252) = .179, p = .004, and the correlation between BSI 
18 GSI scores at end of treatment and 1-month, r(234) = .621, p < .001.   
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 Hypothesis 4. Participants were first separated into those who remained abstinent 
during the three-month follow-up, and those who did not. Abstinence was chosen as the 
independent variable because it is a primary goal of 12-step based treatment. We 
examined the effect of abstinence during the 3 months post-discharge on changes in ASE 
from end of treatment to 3-months post-discharge. The same random coefficient 
regression approach described under hypothesis 2 was utilized; time, abstinence status 
(coded 1 = abstinent and 0 = not abstinent) and the time X abstinence status interaction 
were added to the equation. A significant interaction would mean that the pattern of 
change in ASE was different among those who remained abstinent than those who did 
not.  
 We tested the influence of the potential covariates of pre-treatment substance use, 
pre-treatment AA attendance, and end of treatment motivation by examining their 
correlation with ASE at 3-months. Those variables that were significantly related to ASE 
at 3-months were included as covariates in the previously described analysis. 
 Additional models were estimated among only those who remained abstinent for 
the 3-month post-treatment period; the main effect and interactions for intake Depression 
status and BSI 18 GSI scores at end of treatment were added. As an example, for the 
model including Depression status, change in ASE over time was regressed on the fixed 
effect of time, Depression status at baseline, and their interaction. A significant time X 
depression interaction would mean that change in ASE over time among abstinent 
individuals was dependent upon Depression status at baseline.  This same analysis was 
then repeated for BSI 18 GSI scores at end of treatment. 
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Results  
Hypothesis 1 
At intake, ADUSE scores were normally distributed, with a skew and kurtosis less 
than 1 for the overall score and the four subscales. The ADUSE total distribution was 
more normal than the distributions of the subscales. The ‘Physical & Other Concerns’ 
subscale had a negative skew, such that individuals generally felt more confident to resist 
using in these situations. The opposite was true for the ‘Social/Positive’ scale, which had 
a positive skew, and comprised situations where individuals felt less confident resisting 
substance use. In order to understand areas in which depressed individuals particularly 
may struggle when trying to remain sober, post-hoc independent samples t-tests were 
conducted to determine whether individuals with depression differed from individuals 
without depression at intake in mean scores on the ADUSE subscales.  No significant 
differences were found in mean scores on the ‘Physical and Other Concerns’ or 
‘Social/Positive’ scales. As hypothesized, depressed individuals had significantly lower 
scores on the Negative Affect subscale, t(293) = 3.38, p = .001, and on the Craving/Urges 
subscale, t(293) = 2.48, p = .014.  
 Intake BSI 18 GSI and subscales had a skew and kurtosis less than 2, indicating 
an adequate level of normality. In examining the histograms, BSI 18 GSI and the BSI 18 
depression and anxiety subscales were negatively skewed, with individuals reporting high 
levels of psychological distress at intake. The BSI 18 somatization subscale was 
positively skewed, with most individuals endorsing few somatization symptoms. 
 At intake, both Form 90 days using alcohol or drugs and CSS motivation were 
negatively skewed. Most participants used substances on a high proportion of the 90 days 
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before treatment, and most participants reported a high level of motivation at intake. 
Kurtosis and skew values for these variables were less than 2. 
 At intake, total scores on the BSI 18 GSI were significantly related to depression 
status, r(303) = .498, p < .0001. Those who reported past-month depression were more 
likely to report high psychological distress on the BSI 18 GSI. BSI 18 subscales also 
were significantly and positively related to intake depression status.  
 Intake depression status was significantly and negatively related to overall score 
on the ADUSE, r(295) = -.143, p = .014, such that those with intake depression reported 
less ASE at intake. Intake depression status was negatively related to the ADUSE 
subscales, although the relationship was only significant for the Negative Affect and 
Craving/Urges subscales. Table 3 provides the point-biserial correlations between intake 
depression status and ADUSE scales. 
 On the whole, BSI 18 scores at intake were significantly and negatively related to 
ADUSE scores. Correlations between BSI 18 and ADUSE scales related to negative 
affect were strongest. For example, the correlation between the BSI 18 depression 
subscale and the ADUSE Negative Affect subscale, r(295) = -.263, p < .0001, was larger 
than the correlation between BSI 18 depression and the ADUSE Physical and Other 
Concerns subscale, r(295) = -.111, p = .058. See Table 3 for further specific correlations 
between the BSI 18 and ADUSE scales. 
 We tested for the potential covariates of motivation at intake, lifetime AA 
attendance, and substance use in the 90 days before treatment. While lifetime AA 
attendance was not related to ASE at end of treatment, r(264) = -.011, p = .855, CSS 
motivation at intake was significantly and positively related to end of treatment ASE, 
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r(263) = .167, p = .007. Pre-treatment use also was significantly related to end of 
treatment ASE, r(258) = -.176, p < .0001, such that individuals with higher levels of pre-
treatment use had lower abstinence self-efficacy at end treatment. 
 Partial correlation coefficients were computed for ADUSE scores and 
depression/distress measures, holding constant pre-treatment substance use (see Table 4). 
All correlations decreased as compared to correlations that did not include pre-treatment 
use as a covariate (see Table 3). For example, the point-biserial correlation between 
intake depression and ADUSE total score became non-significant, rp(292) = -.113, p = 
.054. Controlling for motivation did not affect the relationship between the measures of 
psychological distress and the ADUSE scale – if anything it slightly increased the 
strength of the correlations.  
 In the following analyses ADUSE total and BSI 18 GSI are used as independent 
variables. BSI 18 subscales were correlated similarly with ADUSE scores (see Table 3).  
Hypothesis 2 
Mean ADUSE scores were 1.96 (SD = 0.87) at intake, 2.39 (SD = 0.85) at mid-
treatment, and 2.52 (SD = 0.85) at end of treatment. Mean scores on the BSI 18 Global 
Severity Index (GSI) during treatment were 63.32 (SD = 10.07) at intake, 55.64 (SD = 
8.71) at mid-treatment, and 53.37 (SD = 8.72) at end of treatment. In the BSI 18 manual, 
scores above 63 are considered “positive cases” of psychological distress that warrant 
further evaluation (Derogatis, 2000). 
 Random coefficient regression of within-subject linear changes in ASE showed a 
significant effect of time (γ = .28, SE = .03, p < .0001), indicating that, on average, ASE 
increased significantly during treatment. Analysis of the variance components revealed 
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significant variability in both the ADUSE slope and intercept (see Table 5). The 
significant variability in the intercept indicates that there were differences in ASE at 
baseline between participants, while the significant variability in slope means that there 
was variability in the linear change in ASE – not everyone changed in the same way. The 
significant covariance between the slope and the intercept means that ASE and time were 
related. As might be expected, individuals who came into treatment with higher ASE 
experienced a smaller increase in ASE over time.  
 Next, depression status at intake and its interaction with time were added to the 
model. The linear changes in ASE remained significant, and the effect of depression on 
ASE also was significant (γ = -.28, SE = .10, p = .005). Those with baseline depression 
reported less ASE at all three in-treatment assessments (see Figure 1). The interaction 
between time and Depression was non-significant (γ = .07, SE = .06, p = .27), which 
means that the degree of change in ASE over time did not vary as a function of 
Depression status. Adding Depression status to the model accounted for 3.84% of the 
variance in between-subject differences in ASE. 
 When BSI 18 GSI scores at intake and their interaction with time were added to 
the model (in place of Depression status), the within-subject linear changes in ASE no 
longer showed a significant effect of time (γ = .20, SE = .19, p = .28), suggesting that 
intake BSI 18 GSI scores were more strongly related to change in ASE than the passing 
of time. The effect of BSI 18 GSI scores on ASE was significant (γ = -.02, SE = .005, p < 
.0001), such that individuals with higher scores on the BSI 18 at baseline had lower ASE 
scores at intake, mid-treatment, and end of treatment. The BSI 18 X Time interaction was 
non-significant (γ = .001, SE = .003, p = .67): knowing participants’ BSI 18 GSI scores at 
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baseline did not help explain how their ASE scores changed during treatment. In both this 
analysis and the Depression status analysis, the variance components were essentially the 
same as in Table 5. Adding BSI 18 scores to the model accounted for 11.77% of the 
between-subject differences in ASE.  
 Because BSI 18 scores were obtained at each in-treatment interview, BSI 18 
scores were treated as a time-varying covariate in a separate analysis. There was a 
significant effect of time on ASE (γ = .17, SE = .03, p < .0001), as well as a significant 
effect of time-varying BSI 18 scores on ASE (γ = -.02, SE = .003, p < .0001). While BSI 
18 scores at each time point were correlated with ASE scores at that same time point, 
change in BSI 18 scores did not account for differences in the slopes of ASE scores over 
time. In other words, the trajectory of change in BSI 18 did not influence the trajectory of 
change in ASE. Analysis of the covariance estimates revealed some significant variability 
(see Table 6). The ASE intercept X slope covariance was still significant (γ = .26, SE = 
.10, p = .01), indicating that those with higher abstinence self-efficacy at baseline 
experienced smaller changes in ASE over time. No variability was found in the BSI 18 
intercept (i.e., everyone had high BSI 18 scores at intake), but there was significant 
variability in the BSI 18 slope during treatment as well as between the intercept and the 
slope (see Table 6). Individuals who started with high BSI 18 GSI scores experienced 
more change in scores during treatment than those who started with low scores, 
potentially a result of regression to the mean. 
  Because intake motivation and pre-treatment use were significantly related to end 
of treatment ASE (see Hypothesis 1), they were individually added to the RCR analyses 
as covariates: first with BSI 18 as a fixed effect, then with BSI 18 as a time-varying 
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covariate. RCR showed a significant main effect of pre-treatment use on ASE (γ = -.005, 
SE = .002, p = .0006). However, adding pre-treatment use to this model did not alter the 
results found when BSI 18 and its interaction with time were added to the model. Similar 
results were found when pre-treatment use was added to the model with BSI 18 as a time-
varying covariate.  
 When baseline motivation was added to the RCR model in place of pre-treatment 
use, it behaved similarly to pre-treatment use: motivation did not alter previous findings, 
but did have a significant main effect on ASE (γ = .07, SE = .02, p < .0001). This was 
also the case for the model with BSI 18 at baseline and its interaction with time added to 
the model, and when BSI 18 was treated as a time-varying covariate.  In sum, with or 
without the addition of covariates, the findings regarding the relationship of depression 
and psychological distress on changes in self-efficacy during treatment were identical. 
Hypothesis 3 
At 1- and 3-months post-treatment, the distributions of InDUC-2R scores and 
Form-90 PDA were non-normal. Mean InDUC-2R scores were 10.85 at 1-month (SD = 
18.58), with a skew of 2.00 and kurtosis of 3.12 (see Figure 2). At 3-months, mean 
InDUC-2R scores were 11.74 (SD = 24.07), with a skew of 2.63 and kurtosis of 6.52. 
This compares with a mean InDUC-2R score of 65.00 (SD = 24.77) at intake. The 
average Form-90 percent days abstinent was 93.95% at 1-month (SD = 17.55) and 
93.11% at 3-months (SD = 17.18). Skew values for PDA were -3.82 and -3.55 at 1- and 
3-months respectively, and kurtosis values were 14.99 and 13.46 at those same time 
points.  
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 These non-normal values may be related to the disproportionate number of 
participants who reported receiving additional treatment for substance dependence after 
treatment departure (e.g., outpatient or inpatient treatment, detoxification services, or 
sober living environment). At the 1-month follow-up, 82.9% reported receiving 
continuing care; this group had a mean PDA of 97.47% (SD = 10.32) as compared to 
those who did not receive additional treatment and reported a mean PDA of 77.25% (SD 
= 31.01). At 3-months, 75.9% of participants said they had received additional treatment 
for substance dependence since the 1-month follow-up, and these treatment receivers had 
a mean PDA of 96.89% (SD = 11.15). Those who had not received additional treatment 
reported a mean PDA of 81.26% (SD = 25.58). The difference in pre-treatment use (a 
marker of dependence severity) between those who received additional services at 3-
months and those who did not was non-significant, t(243) = -.391, p = .696. 
 Using ordinary least squares regression, depression status at intake did not 
significantly predict outcomes at 1- or 3-months. Similar non-significant results were 
found with end of treatment BSI 18 GSI scores as a predictor, except that these scores 
significantly predicted 3-month InDUC-2R scores, F(1, 154) = 6.90, p = .009, such that 
those with higher BSI 18 GSI scores at end of treatment reported more consequences 
from substance use at 3-months. BSI 18 GSI end of treatment scores accounted for 4.3% 
of the variance in 3-month InDUC-2R scores. Figure 3 depicts the relationship between 
these two variables. BSI 18 GSI scores at 1-month did not significantly predict InDUC-
2R or PDA at 3-months. 
 When end of treatment BSI 18 GSI scores and depression status were used as 
predictors for 1-month outcomes, the regression equation was non-significant for InDUC-
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2R scores, F(2, 176) = 2.68, p = .071, as well as PDA, F(2, 230) = 1.73, p = .180. 
Including depression status and end of treatment and 1-month BSI 18 GSI scores in a 
regression model significantly predicted 3-month InDUC-2R scores, F(3, 144) = 2.71, p 
= .048. The combination of predictors accounted for 5.3% of the variance in substance 
use consequences at 3-months. Only BSI 18 GSI scores at end of treatment made a 
significant contribution to this model, t(146) = 2.164, p = .032. These three predictors did 
not significantly predict PDA at 3-months, F(3, 202) = .913, p = .436. 
Hypothesis 4 
Mean ADUSE scores were 2.52 (SD = 0.85) at end of treatment, 2.53 (SD = 0.93) 
at 1-month post-treatment, and 2.61 (SD = .91) at 3-months post-treatment. As a whole, 
scores on the ADUSE were static during the post-treatment period, increasing by .08 
from end of treatment to the 3-month follow-up. Average BSI 18 GSI scores were also 
fairly stable in this period: 53.37 (SD = 8.72) at end of treatment, 51.23 (SD = 9.25) at 1-
month, and 53.31 (SD = 9.77) at 3-months post-treatment.  
 RCR showed a trend towards increased ASE over time after treatment, but this 
effect was not statistically significant (γ = 0.06, SE = 0.03, p = .08). Analyses of the 
variance components revealed significant variability in the change in ASE over time (see 
Table 7). Specifically, there was significant variation in both the intercept and slope, 
meaning that participants had different levels of ASE at end of treatment and that the 
trajectory of change in ASE from end of treatment to 3 months post-treatment also varied 
between subjects. The covariance was not significant: ASE scores at end of treatment 
were unrelated to the trajectory of change post-treatment.   
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 When abstinence status at 3 months was added to the model, the effect of time on 
post-treatment ASE remained non-significant. Neither the effect of abstinence status on 
ASE (γ = 0.15, SE = 0.11, p = .17) nor the interaction between time and abstinence status 
was significant (γ = 0.03, SE = 0.07, p = .68). Knowing participants’ abstinence status at 
3 months post-discharge did not provide information about their level of ASE during that 
period, and changes in ASE post-treatment did not differ for those who were abstinent 
versus those who used substances in the 3-months after treatment departure (see Figure 
4). The addition of abstinent status to the model accounted for 3.2% of the between-
subject variance in ASE scores. We controlled for baseline use and end of treatment 
motivation because of their significant relationship with 3-month ASE, but doing so did 
not alter the reported results. 
 The next model only included those who remained abstinent from post-treatment 
to 3-months (N = 156). In this group, the effect of time was non-significant, γ = 0.07, SE 
= 0.05, p = .15, such that ASE did not change significantly post-treatment. There was 
significant variability in the variance estimates (see Table 8). The significant intercept 
indicated that there was variability in end of treatment ASE. The covariance between the 
slope and intercept was non-significant: knowing the level of end of treatment ASE did 
not provide information about the degree of change in ASE post-treatment. The 
significant slope meant that there was variability in the changes in ASE post-treatment. 
 When intake depression status and its interaction with time were added to the 
model, the effect of time remained non-significant, γ = 0.02, SE = 0.05, p = .70. 
Similarly, both the effect of depression status on post-treatment ASE (γ = -0.13, SE = 
0.14, p = .34) and the interaction of depression status and time were non-significant (γ = 
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0.14, SE = 0.10, p = .15).  ASE levels post-treatment and their changes over time did not 
depend on intake depression. The addition of depression accounted for 3.8% of the 
between-subject variance in ASE scores. 
 Next, BSI 18 GSI end of treatment scores were added to the abstinent-only model 
in place of depression status. RCR revealed a marginally significant effect of time on 
ASE, γ = -0.62, SE = 0.31, p = .049, such that ASE decreased somewhat from end of 
treatment to the 3-month follow-up. The main effect of BSI 18 GSI scores was also 
significant, γ = -0.03, SE = 0.01, p < .0001. Individuals with low scores on the BSI 18 at 
end of treatment had low ASE scores at the three recorded time points. Covariance 
parameter estimates in this model and the depression status model were similar to those 
in the original model. BSI 18 GSI end of treatment scores accounted for 17.9% of the 
between-subject variance in ASE scores at end of treatment, 1-month post-treatment, and 
3-months post-treatment.  
 The interaction between BSI 18 GSI end of treatment scores and time was 
significant, γ = 0.01, SE = 0.006, p = .03. Changes in ASE post-treatment for the 
abstinent depended on end of treatment psychological distress. Figure 5 depicts post-
treatment changes in ASE separated by median-split high versus low BSI 18 GSI scores 
at end of treatment. To probe the interaction, we examined the effect of time at three 
levels: mean BSI 18 GSI scores at end of treatment, one standard deviation above the 
mean BSI 18 GSI, and one standard deviation below the mean (Cohen et al., 2003).  The 
effect of time was only significant one standard deviation above the mean, γ = 0.13, SE = 
0.05, p = .005, such that those who reported the most psychological distress at end of 
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treatment also increased significantly in ASE post-treatment, while those with average or 
below average distress did not experience significant increases in ASE post-treatment.  
Discussion 
 The current study aimed to improve our understanding of ASE in emerging adults 
by examining the relationship between ASE, depression and distress, and treatment 
outcomes, as well as by investigating the trajectory of ASE during and after treatment. In 
this sample, there was a clear relationship at intake between SCID-I/P diagnoses of 
substance-induced or primary depression and low abstinence self-efficacy, and self-
reported psychological distress (BSI 18 scores) and low abstinence self-efficacy. The 
characteristic low self-efficacy of depressed individuals was manifest in the significantly 
lower confidence participants with depression felt in regards to their ability to resist 
substance use. Conversely, low self-efficacy may have lead to depression – our findings 
do not permit a directional conclusion. The association between ASE and depression 
corroborates previous findings with cocaine-dependent adults at treatment intake and 
provides information about correlates of abstinence self-efficacy in emerging adults 
(Dolan et al., 2008). Dolan and colleagues used the Beck Depression Inventory in their 
sample; extending this to alternate measures of depression in our sample strengthens 
confidence in this finding. As Bandura (2004) posits in his self-efficacy theory, emotional 
states seem to be important in determining levels of abstinence self-efficacy.  
 Similar to findings from Gwaltney and colleagues (2009), controlling for pre-
treatment use attenuated the baseline relationship between abstinence self-efficacy and 
depression, but the correlations between ASE and depression/distress measures were 
mostly still significant. Although our analysis was slightly different from other studies 
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that controlled for substance use while predicting outcomes from ASE, these partial 
correlations do parallel previous findings indicating that abstinence self-efficacy is 
partially a function of behavior. Without controlling for concurrent or previous substance 
use, the relationship between abstinence self-efficacy and depression is arguably 
overestimated (Gwaltney et al., 2009). While substance use was associated with lower 
ASE, the opposite is also true – less use was associated with higher ASE. This coincides 
with Bandura’s conceptualization of increasing self-efficacy as a function of mastery 
experiences (2004), as well as Marlatt and Gordon’s cognitive-behavioral model of 
relapse in which effective coping responses in high-risk situations are followed by 
increased self-efficacy (1985). Future studies should investigate the time-sequence of 
effective coping or success in abstinence and increased self-efficacy to determine the 
degree to which each variable influences the other, and whether these influences are bi-
directional.  
 Although pre-treatment motivation was related to baseline ASE, controlling for 
motivation did not reduce the relationship between ASE and depression or psychological 
distress. In our sample, motivation and depression both were related to ASE and to each 
other, but motivation did not account for a substantial proportion of the variance in the 
relationship between ASE and depression. DiClemente and colleagues (1994) found that 
motivation (as measured by the URICA) was mostly unrelated to the Alcohol and 
Abstinence Self-Efficacy scale. The slight discrepancy between these two findings may 
relate to using different measures of motivation or different age groups. Understanding 
the relationship between motivation and ASE is important for theoretical clarity: are 
ratings of motivation synonymous to ASE ratings? Future studies should validate the CSS 
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(our measure of motivation), or replicate our findings with a different measure of 
motivation or with a similar age group of emerging adults.   
 Situations in which participants reported low ASE inform our understanding of 
substance-related situations that are most difficult for emerging adults. Like adolescents, 
our sample of emerging adults reported low ASE in Social/Positive situations on the 
ADUSE (Chung & Maisto, 2006). In developing the AASE, DiClemente and colleagues 
(1994) found that age was significantly related to the Social/Positive subscale of the 
AASE, in that younger individuals were less confident in these situations. This is in line 
with our findings. Adolescents and emerging adults are strongly tied to their peers and 
have a difficult time resisting alcohol or drugs in social situations when positive emotions 
are expected to follow. Our sample reported high abstinence self-efficacy in Physical & 
Other Concerns situations, suggesting that such situations are uncommon for this group 
(e.g., injury or headache), or that they feel particularly well equipped to deal with them. 
This study offered some support for the former, in that most participants reported very 
low levels of somatization on the BSI 18, which would correspond with low experience 
with Physical & Other Concerns situations. Understanding high-risk situations for 
emerging adults can help clinicians who work with this population: In general, clinicians 
should focus on relapse prevention for positively valenced social situations instead of 
situations related to physical concerns. However, this is a hypothetical leap because we 
only measured situations in which emerging adults thought that they would relapse – not 
those in which they actually did. In addition, high-risk situations may vary from 
individual to individual. Clinicians should assess ASE in different situations and 
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complete a functional analysis for relapse situations to determine antecedents as future 
therapy targets. 
 As hypothesized, participants with depression and high psychological distress 
reported significantly lower ASE in Negative Affect situations on the ADUSE than those 
with low psychological distress and no depression. Depression and BSI 18 scores also 
were significantly related to the other ADUSE subscales, although negative correlations 
were strongest with the Negative Affect subscale. Compared to participants without 
intake depression, those with depression also had significantly less ASE in craving/urges 
situations on the ADUSE. Marlatt and Gordon (1985) highlighted the general importance 
of negative affect situations as high-risk situations for relapse, which may be particularly 
true for those with depression because they are in a constant state of negative affect. 
Clinicians should help depressed individuals consider ways to cope with negative affect 
situations and deal with craving and urges without resorting to alcohol or drugs. 
 Similar to previous findings, abstinence self-efficacy increased during treatment 
(Goldbeck et al., 1997; Ilgen et al., 2005; Wong et al., 2004). Because abstinence self-
efficacy is one of the best predictors of outcomes, increases in abstinence self-efficacy 
during treatment bode well for treatment outcomes (Ilgen et al., 2005; Moos & Moos, 
2006). Future research should investigate the mechanisms by which self-efficacy 
increases. Bandura (2004) has suggested that self-efficacy may increase through social 
modeling. This might happen at CYF when speakers from AA visit and share how they 
have remained sober. Bandura also cited social and verbal persuasion as an avenue for 
increased self-efficacy. Counselors and peers might convince an individual of his or her 
ability to maintain sobriety. It seems that increases in abstinence self-efficacy are a by-
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product of a month spent in a controlled environment, among peers, learning about the 12 
steps. How does this happen? At this point, any consideration of mechanisms of action is 
pure speculation, but future research may uncover how ASE increases during treatment. 
 We also found that those with intake depression or higher psychological distress 
had consistently lower levels of ASE during treatment. Similar to Hypothesis 1, in which 
high intake ASE was negatively related to intake depression and BSI 18 GSI scores, low 
ASE and high distress were related throughout treatment. Although the difference in ASE 
between the depressed and non-depressed was statistically significant throughout 
treatment, the clinical significance of this difference is unknown. Future research should 
investigate whether this gap in ASE is clinically important, or accounts for the 
traditionally poorer outcomes of the depressed (Grant et al., 2004). 
 Contrary to our predictions, in-treatment abstinence self-efficacy increased 
similarly for those who were depressed and those who were not, and increased similarly 
regardless of baseline BSI 18 scores. Even though depressed individuals had consistently 
low levels of ASE, they still experienced similar increases in ASE during treatment. CYF 
does provide additional mental health treatment for the depressed (medications and 
individual therapy), which could have helped them to achieve similar increases in ASE. 
However, these findings suggest that ASE operates similarly in the depressed, especially 
when considering that ASE is equally predictive of outcomes for samples with and 
without comorbidity (Warren et al., 2007). It is a hopeful finding for clinicians because it 
suggests that they can help individuals with comorbid depression and substance 
dependence. Future research should work to increase levels of ASE in this depressed 
group. 
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 Changes in ASE during treatment seemed to be more sensitive to levels of 
psychological distress as measured by the BSI 18 than to intake depression status. When 
modeled separately, BSI 18 scores at intake accounted for 12% of the between-subject 
differences in ASE during treatment, while intake depression status accounted for only 
4% of the between-subject differences in ASE. In addition, when BSI 18 scores were 
added to the model of in-treatment ASE, the effect of time on ASE became non-
significant. This finding suggests that changes in ASE over time had more to do with BSI 
18 scores than time itself. Improvements in BSI 18 scores during treatment may be 
driving changes in ASE. When depression was added to the model, the effect of time was 
still significant. The BSI 18 may be a more sensitive and reliable measure of depression 
than the SCID-I/P for substance users, or it may be tapping different aspects of 
psychological distress that are more related to ASE than the DSM-IV criteria for 
depression. The BSI 18 is easy to administer, and could be a useful tool to monitor 
progress during treatment. 
 Overall, BSI 18 scores and intake depression status did not predict 1-month or 3-
month substance use outcomes: thus hypothesis 3 was not supported. This finding 
contradicts a body of literature in which depression has been found to predict poorer 
treatment outcomes (Dodge et al., 2005; Greenfield et al., 1998). We could not evaluate 
whether intake depression status or BSI 18 score was a better predictor of outcomes for 
two reasons: (1) intake depression and BSI 18 scores were strongly related and hence 
multi-collinear, and (2) the variables did not predict outcomes individually, so it did not 
make sense to continue to the combined model. Further studies with longer follow-up 
periods need to be conducted among emerging adults to examine the predictive power of 
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depression on outcomes. Six and 12-month follow-ups for this study have yet to be 
analyzed, and may answer this question. 
 The fact that depression did not predict outcomes may mean that the two are 
unrelated, but in this case, the narrow range of outcomes seems to be a more logical 
explanation. Almost everyone was abstinent at the follow-up assessments (93% PDA on 
average). Furthermore, few negative consequences from substance use were reported. 
The exemplary outcomes of this sample may have more to do with their aftercare 
situation than the effects of treatment: at 1 month post-treatment, 83% of the sample 
reported receiving additional services for substance dependence, and this group had an 
average PDA of 97.5 versus those who did not receive continuing care (mean PDA of 
77.3). These findings speak to the importance of extended treatment for emerging adults 
who have a goal of abstinence from substance use. However, those who received 
continuing care were not necessarily more dependent – there was no difference in pre-
treatment substance use between the groups who received continuing care at 1-month and 
those who did not – but the difference in substance use outcomes was substantial.  
The drop in reported consequences on the InDUC-2R from intake to post-
treatment (from an average of 65.0 to 11.0) is a noteworthy feature in this sample that 
diverges from many adult samples that experience consequences long after substance use 
ceases. Intake InDUC-2R scores in this sample were comparable to an adult outpatient 
sample, but considerably less than an adult inpatient sample (Tonigan & Miller, 2002). At 
this point in their lives, emerging adults seem to experience fewer, or more fleeting 
consequences.  
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 Examining post-treatment ASE, no significant changes were found from end of 
treatment to 3-months, and abstinence status at 3-months did not moderate ASE 
trajectories. This finding was peculiar and unexpected. In line with Bandura’s theory of 
increasing self-efficacy through mastery and performance experiences (2004), it would 
seem that individuals who remain abstinent would experience increases in ASE because 
of the strong relationship between behavior and ASE. For those in continuing care, we 
would expect self-efficacy to continue to increase similarly to those in treatment. Brown 
and colleagues (2002) did find that increases in ASE during continuing care occurred 
only in a Relapse Prevention continuing care group, and did not occur for a 12-step 
oriented aftercare group. Because CYF is a 12-step oriented program, clinicians probably 
prescribe 12-step oriented aftercare. Similar to Brown et al., 12-step oriented aftercare 
may account for the static ASE we found post-treatment. The high percentage of 
abstinent emerging adults also may be relevant to the null findings because of the 
restricted range of outcomes. Also, follow-up rates were low, decreasing power and 
overall confidence in the generalizability of these findings. An independent samples t-test 
between those who completed the ADUSE at least one post-treatment follow-up and 
those who did not revealed no significant differences in end-treatment ADUSE scores or 
3-month PDA rates. A post-hoc analysis could look specifically at those who received 
residential continuing care and determine whether self-efficacy continued to grow in this 
sub-group. If it did not, this would support the specific nature of growth of ASE in 
residential treatment. It is possible that ASE reaches a ceiling by end of treatment.  
 When looking only at the 141 participants who remained abstinent until the 3-
month follow-up and had ADUSE data at two of the three included time points, there 
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were no significant changes in post-treatment ASE. Similar to the in-treatment findings, 
depression did not moderate changes in ASE post-treatment. Again, ASE seems to be 
operating similarly for the depressed and non-depressed, which provides added support 
for in-treatment findings.  
 BSI 18 end of treatment scores did predict ASE at the follow-ups. Participants 
who experienced high psychological distress at end of treatment had less ASE at end of 
treatment, 1-month, and 3-months post-treatment.  The importance of BSI 18 at end of 
treatment over depression status at intake in predicting ASE during the follow-up period 
points to the importance of using more proximal variables (end of treatment versus intake 
measures) when predicting ASE. On the other hand, BSI 18 score may have better 
predicted ASE because they are a continuous measure of distress (versus the dichotomous 
SCID-I/P depression status).The interaction was significant: BSI 18 end of treatment 
scores moderated changes in ASE post-treatment among the abstinent, and accounted for 
17.9% of the between-subject variance in ASE. When this interaction was deconstructed, 
changes in ASE post-treatment only occurred for those with end of treatment BSI 18 GSI 
scores that were one standard deviation above the mean. This specific effect for those 
with high psychological distress deserves further investigation: if this group sought 
additional treatment, perhaps they needed the extra boost of additional care to elevate 
their ASE. For those with high distress that discontinued formal care, perhaps the effect 
of AA meetings or confidence-building successes outside of a confined setting led to 
differential growth in ASE. 
 Our findings must be considered in light of several limitations. The sample was 
three-quarters male, but depression occurs more frequently among women in the general 
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U.S. population (Kessler et al., 2005). In our sample, those in the depressed group were 
significantly more likely to be female than those in the non-depressed group. Future 
research should examine depression and ASE among a larger sample of female treatment 
seekers. Because they sought inpatient treatment and used substances an average of 70 
out of the 90 days before treatment, this group was more dependent than most emerging 
adults. Abstinence self-efficacy may operate differently in a less severe sample. The 
collapsing of two SCID diagnostic categories may have obscured or biased findings: 
those with current MDD reported less substance use at baseline than those with 
substance-induced depression. Also, the overrepresentation of heroin users in the 
depressed group and overrepresentation of marijuana users in the non-depressed group 
may have implications for generalizability. The sample was primarily Caucasian and 
findings may not generalize to ethnic minority samples. Follow-up rates were low at 1 
month (42.9%) and 3 months (64.0%) for self-reported assessments, versus 84.8% for 1- 
and 3-month phone or in-person interviews, thus affecting the testability of hypotheses 
that focused on post-treatment outcomes. Future analyses should examine how well ASE 
predicts treatment outcomes, which was not done in the current study. Including the six 
and 12-month follow-ups in future work with this sample will provide a more complete 
picture of changes in ASE during and after treatment. 
 Despite these limitations, this study had several strengths. Large inpatient clinical 
samples are notoriously hard to reach, and this study included multiple assessment points 
with such a population. It focused specifically on the understudied category of emerging 
adults with depression. Emerging adults have high rates of substance use, and those who 
have depression tend to continue drinking into adulthood, which adds import to the study 
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of comorbidity in emerging adults (Costanzo et al., 2007). Our sample did not exclude 
any substance dependence categories and included poly-drug users, which increases the 
external validity of our findings because emerging adults are often poly-drug users 
(Chung & Maisto, 2006).  
 The goal of this study was to examine changes in abstinence self-efficacy over 
time and its relation to depression and psychological distress in a specific sample: 
emerging adults attending a 12-step focused 28-day inpatient treatment program. Most of 
our findings corresponded with previous findings. At intake, emerging adults without 
depression were more confident in their ability to resist substance use. The entire sample 
reported low ASE in positive affect social situations. In the depressed, the lowest levels 
of ASE were reported in negative affect situations. Abstinence self-efficacy increased 
during treatment for the entire sample regardless of level of depression or psychological 
distress. The benefits of long-term aftercare for this dependent sample of emerging adults 
were apparent in post-treatment abstinence rates. 
 In some ways, our findings diverged from expectations: depressed individuals 
were able to increase their self-efficacy during treatment, even though they had 
consistently lower levels of ASE as compared to non-depressed individuals. If these 
findings hold for longer-term 6 and 12-month follow-ups, clinicians may have some 
assurance that emerging adults with depression can experience increases in abstinence 
self-efficacy. Future analyses should consider depression diagnoses or BSI 18 scores as a 
predictor of longer-term outcomes because of the effects of early continuing care and 
restricted range of drinking outcomes in this sample. In addition, investigations should 
determine whether increases in ASE are specific to 12-step treatment, if changes in ASE 
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mediate better outcomes, and whether ASE reaches a peak after 28 days. In this way, we 
will better understand both the construct of ASE and the experiences of emerging adults 
with depression and substance dependence. 
  53
References 
 
Adamson, S. J., Sellman, J. D., & Frampton, C. M. (2009). Patient predictors of alcohol 
treatment outcome: A systematic review. Journal of Substance Abuse Treatment, 
36(1), 75-86. 
Annis, H. M., & Graham, J. M. (1988). Situational confidence questionnaire (SCQ-39): 
User's guide. Toronto, Ontario, Canada: Addiction Research Foundation. 
Arnett, J. J. (2000). Emerging adulthood. A theory of development from the late teens 
through the twenties. The American Psychologist, 55(5), 469-480. 
Arnett, J. J. (2005). The developmental context of substance use in emerging adulthood. 
Journal of Drug Issues, 35(2), 235-254. 
Asner-Self, K. K., Schreiber, J. B., & Marotta, S. A. (2006). A cross-cultural analysis of 
the Brief Symptom Inventory-18. Cultural Diversity & Ethnic Minority 
Psychology, 12(2), 367-375. 
Bandura, A. (1989). Human agency in social cognitive theory. American Psychologist, 
44, 1175-1184. 
Bandura, A. (2004). Swimming against the mainstream: The early years from chilly 
tributary to transformative mainstream. Behaviour Research and Therapy, 42(6), 
613-630. 
Blanchard, K. A., Morgenstern, J., Morgan, T. J., Labouvie, E. W., & Bux, D. A. (2003). 
Assessing consequences of substance use: Psychometric properties of the 
inventory of drug use consequences. Psychology of Addictive Behaviors, 17(4), 
328-331.  
  54
Bradizza, C. M., Stasiewicz, P. R., & Paas, N. D. (2006). Relapse to alcohol and drug use 
among individuals diagnosed with co-occurring mental health and substance use 
disorders: a review. Clinical Psychology Review, 26(2), 162-178. 
Brown, T. G., Seraganian, P., Tremblay, J., & Annis, H. (2002). Process and outcome 
changes with relapse prevention versus 12-Step aftercare programs for substance 
abusers. Addiction, 97(6), 677. 
Burleson, J. A., & Kaminer, Y. (2005). Self-efficacy as a predictor of treatment outcome 
in adolescent substance use disorders. Addictive behaviors, 30(9), 1751-1764. 
Chung, T., & Maisto, S. A. (2006). Relapse to alcohol and other drug use in treated 
adolescents: Review and reconsideration of relapse as a change point in clinical 
course. Clinical Psychology Review, 26(2), 149-161. 
Cohen, J., Cohen, P., West, S. G., & Aiken, L. S. (2003). Applied multiple 
regression/correlation analysis for the behavioral sciences. Mahwah, NJ: L. 
Erlbaum Associates. 
Cornelius, J. R., Maisto, S. A., Martin, C. S., Bukstein, O. G., Salloum, I. M., Daley, D. 
C., ...Clark, D. B. (2004). Major depression associated with earlier alcohol relapse 
in treated teens with AUD. Addictive behaviors, 29(5), 1035-1038. 
Costanzo, P. R., Malone, P. S., Belsky, D., Kertesz, S., Pletcher, M., & Sloan, F. A. 
(2007). Longitudinal differences in alcohol use in early adulthood. Journal of 
Studies on Alcohol and Drugs, 68(5), 727-737. 
Derogatis, L. R. (2000). BSI 18: Administration, scoring, and procedures manual. 
Minneapolis, MN: National Computer Systems. 
  55
Derogatis, L. R. (1993). The Brief Symptom Inventory (BSI): Administration, scoring and 
procedures manual (3rd ed.). Minneapolis, MN: National Computer Systems. 
Derogatis, L. R. (1994). Symptom Checklist-90-R (SCL-90-R) Administration, scoring 
and procedures manual (3rd ed.). Minneapolis, MN: National Computer Systems. 
DiClemente, C. C., Carbonari, J. P., Montgomery, R. P. G., & Hughes, S. O. (1994). The 
Alcohol Abstinence Self-Efficacy scale. Journal of Studies on Alcohol, 55(2), 
141-148. 
Dodge, R., Sindelar, J., & Sinha, R. (2005). The role of depression symptoms in 
predicting drug abstinence in outpatient substance abuse treatment. Journal of 
Substance Abuse Treatment, 28(2), 189-196. 
Dolan, S. L., Martin, R. A., & Rohsenow, D. J. (2008). Self-efficacy for cocaine 
abstinence: pretreatment correlates and relationship to outcomes. Addictive 
Behaviors, 33(5), 675-688.  
Faul, F., Erdfelder, E., Lang, A., & Buchner, A. (2007). G*Power 3: A flexible statistical 
power analysis program for the social, behavioral, and biomedical sciences. 
Behavior Research Methods, 39(2), 175-191. 
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (1995). The Structured Clinical 
Interview for DSM-III-R Personality Disorders (SCID-II): II. Multi-site test-retest 
reliability study. Journal of Personality Disorders, 9(2), 92-104. 
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (2002). Structured Clinical 
Interview for DSM-IV-TR Axis I Disorders, research version, patient edition 
(SCID-I/P). New York: Biometrics Research, New York State Psychiatric 
Institute. 
  56
Flynn, H. A., Walton, M. A., Curran, G. M., Blow, F. C., & Knutzen, S. (2004). 
Psychological distress and return to substance use two years following treatment. 
Substance Use & Misuse, 39(6), 885-910. 
Markman Geisner, I., Larimer, M. E., & Neighbors, C. (2004). The relationship among 
alcohol use, related problems, and symptoms of psychological distress: Gender as 
a moderator in a college sample. Addictive Behaviors, 29(5), 843-848. 
Gillaspy, J. A., Jr., & Campbell, T. C. (2006). Reliability and validity of scores from the 
inventory of drug use consequences. Journal of Addictions & Offender 
Counseling, 27, 11. 
Goldbeck, R., Myatt, P., & Aitchison, T. (1997). End-of-treatment self-efficacy: A 
predictor of abstinence. Addiction, 92(3), 313-324. 
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., 
...Kaplan, K. (2004). Prevalence and co-occurrence of substance use disorders and 
independent mood and anxiety disorders: Results from the National 
Epidemiologic Survey on Alcohol and Related Conditions. Archives of General 
Psychiatry, 61(8), 807. 
Greenfield, S. F., Hufford, M. R., Vagge, L. M., Muenz, L. R., Costello, M. E., & Weiss, 
R. D. (2000). The relationship of self-efficacy expectancies to relapse among 
alcohol dependent men and women: A prospective study. Journal of Studies on 
Alcohol, 61(2), 345. 
Greenfield, S. F., Weiss, R. D., Muenz, L. R., Vagge, L. M., Kelly, J. F., Bello, L. R., & 
Michael, J. (1998). The effect of depression on return to drinking: A prospective 
study. Archives of General Psychiatry, 55(3), 259-265. 
  57
Gwaltney, C. J., Shiffman, S., & Sayette, M. A. (2005). Situational correlates of 
abstinence self-efficacy. Journal of Abnormal Psychology, 114(4), 649-660. 
Gwaltney, C. J., Metrik, J., Kahler, C. W., & Shiffman, S. (2009). Self-efficacy and 
smoking cessation: A meta-analysis. Psychology of Addictive Behaviors, 23(1), 
56-66. 
Hiller, M. L., Broome, K. M., Knight, K., & Simpson, D. D. (2000). Measuring self-
efficacy among drug-involved probationers. Psychological Reports, 86(2), 529-
538. 
Ilgen, M., McKellar, J., & Tiet, Q. (2005). Abstinence self-efficacy and abstinence 1 year 
after substance use disorder treatment. Journal of Consulting and Clinical 
Psychology, 73, 1175–1180. 
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., ...Wang, 
P.S. (2003). The epidemiology of Major Depressive Disorder: Results from the 
National Comorbidity Survey Replication (NCS-R). Journal of the American 
Medical Association, 289(23), 3095-3105. 
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., & 
Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of 
DSM-IV disorders in the National Comorbidity Survey Replication. Archives of 
General Psychiatry, 62, 593-602.  
Kranzler, H. R., Kadden, R. M., Babor, T. F., & Tennen, H. (1996). Validity of the SCID 
in substance abuse patients. Addiction, 91(6), 859-868.  
  58
Maddux, J. E., & Meier, L. J. (1995). Self-efficacy and depression. In J. E. Maddux (Ed.), 
Self-efficacy, adaptation, and adjustment: Theory, research, and application (pp. 
143–169). New York, NY: Springer. 
Maddux, J. E. (1991). Self-efficacy. In C. R. Snyder & D. R. Forsyth (Eds.), Handbook of 
social and clinical psychology: The health perspective (pp. 57-78). New York, 
NY: Pergamom. 
Marlatt, G. A., & Gordon, J. R. (1985). Relapse prevention: Maintenance strategies in 
the treatment of addictive behaviors. New York, NY: Guilford. 
McKellar, J., Ilgen, M., Moos, B. S., & Moos, R. (2008). Predictors of changes in 
alcohol-related self-efficacy over 16 years. Journal of Substance Abuse 
Treatment, 35(2), 148-155. 
Miller, W. R., & Del Boca, F. K. (1994). Measurement of drinking behavior using the 
Form 90 family of instruments. Journal of Studies on Alcohol, S12, 112-118. 
Moos, R. H. (2008). Active ingredients of substance use-focused self-help groups. 
Addiction, 103, 387-396. 
Moos, R. H., & Moos, B. S. (2006). Rates and predictors of relapse after natural and 
treated remission from alcohol use disorders. Addiction, 101(2), 212-222. 
Moss, H. B., Kirisci, L., & Mezzich, A. C. (1994). Psychiatric comorbidity and self-
efficacy to resist heavy drinking in alcoholic and nonalcoholic adolescents. 
American Journal on Addictions, 3(3), 204-212. 
Project MATCH Research Group (1993). Project MATCH (Matching Alcoholism 
Treatment to Client Heterogeneity): Rationale and methods for a multisite clinical 
  59
trial matching patients to alcoholism treatment. Alcoholism: Clinical and 
Experimental Research, 17(6), 1130 - 1145.  
Ramo, D. E., & Brown, S. A. (2008). Classes of substance abuse relapse situations: a 
comparison of adolescents and adults. Psychology of Addictive Behaviors, 22(3), 
372-379.  
Ramo, D. E., Anderson, K. G., Tate, S. R., & Brown, S. A. (2005). Characteristics of 
relapse to substance use in comorbid adolescents. Addictive Behaviors, 30(9), 
1811-1823. 
Rice, C. (2007). Retest reliability of self-reported daily drinking: Form 90. Journal of 
Studies on Alcohol and Drugs, 68(4), 615-618. 
Rohde, P. (2009). Comorbidities with adolescent depression. In S. Nolen-Hoeksema & L. 
M. Hilt (Eds.), Handbook of depression in adolescents (pp. 139-177). New York, 
NY: Routledge. 
Ross, H. E., Swinson, R., Doumani, S., & Larkin, E. J. (1995). Diagnosing comorbidity 
in substance abusers: A comparison of the test-retest reliability of two interviews. 
The American Journal of Drug and Alcohol Abuse, 21(2), 167-185. 
Schafer, J. L., & Graham, J. W. (2002). Missing data: Our view of the state of the art. 
Psychological methods, 7(2), 147-177. 
Segal, D. L., Kabacoff, R. I., Hersen, M., Van Hasselt, V. B., & Ryan, C. F. (1995). 
Update on the reliability of diagnosis in older psychiatric outpatients using the 
structured clinical interview of DSM IIIR. Journal of Clinical Geropsychology, 
1(4), 313-321. 
  60
Shiffman, S., Balabanis, M. H., Paty, J. A., Engberg, J., Gwaltney, C. J., Liu, K. S., 
...Paton, S. M. (2000). Dynamic effects of self-efficacy on smoking lapse and 
relapse. Health Psychology, 19(4), 315–323. 
Skre, I., Onstad, S., Torgersen, S., & Kringlen, E. (1991). High interrater reliability for 
the Structured Clinical Interview for DSM-III—R Axis I (SCID-I). Acta 
Psychiatrica Scandinavica, 84(2), 167-173.  
Slesnick, N., & Tonigan, J. S. (2004). Assessment of alcohol and other drug use by 
runaway youths: A test-retest study of the Form 90. Alcoholism Treatment 
Quarterly, 22(2), 21-34.  
Substance Abuse and Mental Health Services Administration. (2005). Results from the 
2004 National Survey on Drug Use and Health: National findings (Office of 
Applied Studies, NSDUH Series H-28, DHHS Publication No. SMA 05-4062). 
Rockville, MD. 
Substance Abuse and Mental Health Services Administration (2007). The NSDUH 
Report: Co-occurring Major Depressive Episode (MDE) and Alcohol Use 
Disorder among adults (Office of Applied Studies). Rockville, MD. 
Tomlinson, K. L., Brown, S. A., & Abrantes, A. (2004). Psychiatric comorbidity and 
substance use treatment outcomes of adolescents. Psychology of Addictive 
Behaviors, 18(2), 160-169.  
Tonigan, J. S., Miller, W. R., & Brown, J. M. (1997). The reliability of Form 90: An 
instrument for assessing alcohol treatment outcome. Journal of Studies on 
Alcohol, 58(4), 358-364. 
  61
Tonigan, J. S., & Miller, W. R. (2002). The inventory of drug use consequences 
(InDUC): Test-retest stability and sensitivity to detect change. Psychology of 
Addictive Behaviors, 16(2), 165-168. 
Warren, J. I., Stein, J. A., & Grella, C. E. (2007). Role of social support and self-efficacy 
in treatment outcomes among clients with co-occurring disorders. Drug and 
Alcohol Dependence, 89(2-3), 267-274. 
Westerberg, V. S., Tonigan, J. S., & Miller, W. R. (1998). Reliability of Form 90D: An 
instrument for quantifying drug use. Substance Abuse, 19(4), 179-189. 
Witkiewitz, K., & Marlatt, G. A. (2004). Relapse prevention for alcohol and drug 
problems: That was Zen, this is Tao. The American Psychologist, 59(4), 224-235.  
Wong, C. J., Anthony, S., Sigmon, S. C., Mongeon, J. A., Badger, G. J., & Higgins, S. T. 
(2004). Examining interrelationships between abstinence and coping self-efficacy 
in cocaine-dependent outpatients. Experimental and Clinical 
Psychopharmacology, 12(3), 190-198. 
Zabora, J., Brintzenhofe-Szoc, K., Jacobsen, P., Curbow, B., Piantadosi, S., Hooker, C., 
...Derogatis, L. (2001). A new psychosocial screening instrument for use with 
cancer patients. Psychosomatics, 42(3), 241-246. 
Zanarini, M. C., & Frankenburg, F. R. (2001). Attainment and maintenance of reliability 
of axis I and II disorders over the course of a longitudinal study. Comprehensive 
Psychiatry, 42(5), 369–374. 
Zanarini, M. C., Skodol, A. E., Bender, D., Dolan, R., Sanislow, C., Schaefer, E., 
...Gunderson, J. G. (2000). The Collaborative Longitudinal Personality Disorders 
  62
Study: Reliability of Axis I and II diagnoses. Journal of Personality Disorders, 
14(4), 291–299. 
Zarate, C. A., Jr. (2009). Psychiatric disorders in young adults: Depression assessment 
and treatment. In J. E. Grant & M. N. Potenza (Eds.), Young adult mental health 
(pp. 206 - 230). Oxford, England: Oxford University Press. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  63
Appendix. Study Measures. 
Measure Assessment Point Form 
 Intake Mid-Tx End-Tx 1 mo. 
3 
mos. 
6 
mos. 
12 
mos. 
 
Demographics 
X       Pull 
from 
Records 
Clinical Diagnoses and Symptoms 
Brief Symptom Inventory 18  X X X X X X X I 
Structured Clinical Interview for the 
DSM-IV-TR 
X       I 
Substance Use Frequency 
Form-90 X   X X X X I 
Substance Use Consequences 
Inventory of Drug Use Consequences  X   X X X X S 
Abstinence Self-Efficacy 
Alcohol and Drug Use Self-Efficacy 
Scale  
X X X X X X X S 
Motivation 
Commitment to Sobriety X   X X X X X I 
Note: “I” = interview; “S” = self-administered questionnaire 
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Table 1 
 
Participant Characteristics at Intake as a Function of Past-Month Depression Status 
 
       Depression (N = 99)           No Depression (N = 204)    
                             (n, %)           (n, %)    
Gender 
 Female   34 (34.3)   45 (22.1)   
 Male    65 (65.7)                      159 (77.9)   
Ethnicity 
 Caucasian   95 (96.0)                       192 (94.1)   
 African American    1 (1.0)       3 (1.5)   
 American Indian    2 (2.0)       3 (1.5)   
 Asian American    0 (0.0)       3 (1.5)     
 Other/Unknown    1 (1.0)                  3 (1.5)   
Education 
 Did not complete H.S. 14 (14.1)             36 (17.6)   
 H.S. Diploma/GED  48 (48.5)             84 (41.2)   
 Some College   36 (36.4)             79 (38.7)            
 Assoc./Bachelor’s    1 (1.0)      4 (2.0)            
 Unknown     0 (0.0)      1 (0.5)  
Substance of Choice 
 Alcohol   23 (23.2)             58 (28.4)   
 Opiates   32 (32.3)             35 (17.2)  
 Marijuana   17 (17.2)             64 (31.4)   
 Cocaine   12 (12.1)             24 (11.8)   
  65
 Other      8 (8.0)             12 (5.9)  
 Methamphetamine    5 (5.1)             10 (4.9)  
     Mean (SD)                    Mean (SD)             
Age (years)    20.5 (1.6)                   20.3 (1.6)  
Length of stay (days)   25.1 (6.7)                     25.2 (6.4)  
BSI 18 GSI    70.5 (6.9)                     59.8 (9.5) **  
ADUSE Total      1.8 (1.0)                       2.1 (0.8) *    
Pre-treatment use (out of 90 days) 73.9 (22.1)                     65.9 (26.3)**   
Consequences (InDUC-2R)  79.5 (20.0)                     58.0 (24.0)**  
  
Note. *p < .05; **p < .01; Bolded categories were significantly different for depressed 
versus non-depressed individuals in a chi-squared test; BSI 18 GSI = Brief Symptom 
Inventory 18 Global Severity Index; ADUSE = Alcohol and Drug Use Self-Efficacy 
scale; pre-treatment use is taken from the intake Form-90; InDUC-2R = Inventory of 
Drug Use Consequences; InDUC-2R Total reflects reported consequences related to drug 
use in the 90 days prior to intake.  
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Table 2 
 
Demographic Information at Intake by Depression Category 
 
                           Substance-induced (N = 51)      MDD (N = 48)    
 
      (n, %)           (n, %)    
Gender 
 Female   16 (31.4)   18 (37.5)  
  
 Male    35 (68.6)                        30 (62.5)   
     Mean (SD)                    Mean (SD)             
Age (years)    20.53 (1.50)                   20.50 (1.70)   
Length of stay (days)   24.75 (7.45)                     25.40 (5.89)   
BSI 18 GSI    70.04 (7.39)                     71.00 (6.31)   
ADUSE Total      1.82 (1.04)                       1.75 (0.94)     
Pre-treatment use (out of 90 days) 79.90 (16.98)                     67.60 (25.10)*   
Consequences (InDUC-2R)  84.00 (18.88)                     74.28 (20.31)   
Note. *p < .01; Substance-induced = Substance-Induced Mood Disorder, depressive type, 
past month from the SCID-I/P; MDD = past-month Major Depressive Disorder from the 
SCID-I/P; BSI 18 GSI = Brief Symptom Inventory 18 Global Severity Index; ADUSE = 
Alcohol and Drug Use Self-Efficacy scale; pre-treatment use is pulled from the intake 
Form-90; InDUC-2R = Inventory of Drug Use Consequences; InDUC-2R Total reflects 
reported consequences related to drug use in the 90 days prior to intake.  
 
 
 
 
 
 
 
 
 
  67
Table 3 
 
Correlations between Abstinence Self-Efficacy and Depression Indicators at Intake 
 
Alcohol and Drug Use Self-Efficacy Scale scores (N = 295) 
 
       Total    NA      P  C/U  S/P 
Past month  
Depression     -.143* -.194** -.052  -.144*  -.096 
 
BSI 18 
  Total     -.253*** -.286*** -.174** -.252*** -.148* 
  Depression    -.222*** -.263*** -.111  -.230*** -.153** 
  Anxiety    -.238*** -.293*** -.148*  -.205*** -.163*** 
  Somatization    -.157** -.126*  -.193** -.174** -.039 
Note. *p < .05; **p < .01; ***p < .001; ADUSE subscales include Negative Affect (NA), 
Physical and Other Concerns (P), Craving/Urges (C/U), and Social/Positive (S/P). 
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Table 4 
 
Partial Correlations between Abstinence Self-Efficacy and Depression Indicators 
(Controlling for Substance Use) 
Alcohol and Drug Use Self-Efficacy Scale scores (N = 292) 
       Total    NA      P  C/U  S/P 
Past month  
Depression     -.113 -.169** -.019  -.117*  -.074 
BSI 18 
  Total      -.201** -.244*** -.118*  -.205*** -.109 
  Depression     -.186** -.233*** -.070  -.198** -.126* 
  Anxiety     -.187** -.252*** -.094  -.157** -.125* 
  Somatization     -.099 -.074  -.140*  -.124*  -.005 
Note. *p < .05; **p < .01; ***p < .001; ADUSE subscales include Negative Affect (NA), 
Physical and Other Concerns (P), Craving/Urges (C/U), and Social/Positive (S/P). 
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Table 5 
 
Covariance Estimates for Between-Subjects Effects of Time on In-Treatment ASE 
Abstinence Self-Efficacy (N = 303) 
Variance Component  Parameter Estimate SE Z Value p 
Intercept       τ11      0.42            0.06   7.20         < .0001 
Slope/Intercept Correlation     τ21      -0.06            0.03       -2.16              .03 
Slope Variability      τ22      0.09            0.02        3.88         < .0001  
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Table 6 
 
Covariance Estimates for Between-Subjects Effects of Time on In-Treatment ASE with 
Time-Varying BSI 18 
Abstinence Self-Efficacy (N = 303) 
Variance Component  Parameter Estimate SE Z Value p 
Intercept       τ11      1.27            0.94   1.35            .09 
Slope/Intercept Correlation     τ21       0.26            0.10        2.54              .01 
Slope Variability      τ22      0.03            0.02        1.37            .09  
BSI 18 GSI 
Intercept       τ31     -0.02            0.02  -1.35            .18 
Slope/Intercept Correlation     τ32      -0.004          0.002     -2.66              .008 
Slope Variability      τ33      0.0005        0.0003    1.71            .04  
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Table 7 
 
Covariance Estimates for Between-Subjects Effects of Time on Post-Treatment ASE 
Abstinence Self-Efficacy (N = 303) 
Variance Component  Parameter Estimate SE Z Value p 
Intercept       τ11      0.47            0.07   6.84         < .0001 
Slope/Intercept Correlation     τ21      -0.05            0.03       -1.49              .14 
Slope Variability      τ22      0.09            0.03        2.98            .002  
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Table 8  
 
Between-Subjects Effects of Time on Post-Treatment ASE among the Abstinent 
Abstinence Self-Efficacy (N = 141) 
Variance Component  Parameter Estimate SE Z Value p 
Intercept       τ11      0.39            0.08   4.71         < .0001 
Slope/Intercept Correlation     τ21      -0.04            0.04       -0.90              .37 
Slope Variability      τ22      0.12            0.04        2.77          < .0001  
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Figure 1. Changes in abstinence self-efficacy during treatment as a function of intake 
depression. ADUSE = Alcohol and Drug Use Self-Efficacy scale total.  
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Figure 2. Distribution of substance use consequences at 1-month post-treatment. InDUC-
2R = Total score on Inventory of Drug Use Consequences in the period since discharge. 
InDUC-2R scores can range from zero to 135. In this figure, N = 185, mean InDUC-2R = 
10.85 (SD = 18.58). 
 
 
 
 
 
 
 
 
 
 
 
  75
 
 
3 Months InDUC-2R Total
120.00100.0080.0060.0040.0020.000.00
En
d 
o
f t
re
at
m
en
t B
SI
 
18
 
G
SI
80
70
60
50
40
30
 
Figure 3. The relationship between end of treatment distress & 3-month substance use 
consequences. BSI 18 GSI = Brief Symptom Inventory 18 Global Severity Index. 
InDUC-2R = Inventory of Drug Use Consequences for period from 1 month post-
treatment to 3-months post-treatment. 
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Figure 4. Changes in abstinence self-efficacy post-treatment as a function of 3-month 
abstinence status. ADUSE = Alcohol and Drug Use Self-Efficacy scale total score. 
Abstinence was defined as no substance use in the period from discharge until the  
3-month interview. 
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Figure 5. Changes in abstinence self-efficacy post-treatment as a function of end of  
treatment BSI 18 GSI scores. ADUSE = Alcohol and Drug Use Self-Efficacy scale total. 
BSI 18 GSI = Brief Symptom Inventory 18 Global Severity Index. Low and high BSI 18 
GSI end of treatment scores were determined using a median split. 
 
 
 
 
 
 
 
 
 
 
 
 
